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ABSTRACT 
 
Arginine and Fetal Growth in Ovine Models of Intrauterine Growth Restriction. 
(December 2008) 
Arantzatzu L. Lassala, B.S., National University of Mexico; 
M.S., National University of Mexico 
Co-Chairs of Advisory Committee: Dr. Thomas E. Spencer 
     Dr. Fuller W. Bazer 
 
 
 This research was conducted to test the hypothesis that parenteral 
arginine supplementation is effective in enhancing birth weights of intrauterine 
growth restricted (IUGR) fetuses.  Underfed and prolific ewes were used as 
experimental models.  The first study characterized the pharmacokinetics of 
arginine and citrulline and assessed the potential of citrulline to serve as a 
precursor for enhancing arginine availability in fetal and maternal plasma.  Six 
late pregnant ewes and their fetuses were instrumented to access arterial and 
venous circulations.  Intravenous boluses of 155 mol of L-arginine-HCl or L-
citrulline per kg body weight were administered to each ewe.  Administration of 
citrulline was more effective than arginine in achieving a sustained increase in 
concentrations of arginine in maternal and fetal blood.  Accordingly, the 
clearance rate of citrulline was lower and its biological half-life in maternal blood 
greater, when compared with arginine.  The second experiment determined if 
administration of arginine to underfed ewes is effective in ameliorating or 
preventing IUGR.  Ewes were fed either 100% or 50% of the National Research 
Council recommended nutrient requirements for pregnant sheep.  Between Day 
60 of pregnancy and parturition control-fed ewes received saline solution and 
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underfed ewes received either saline solution or L-arginine-HCl solution (155 
mol of arginine/kg body weight) intravenously three times daily (n=5 / treatment 
group).  Birth weights of lambs were lower in saline-infused underfed ewes.  
There was no difference in birth weights of lambs from control-fed and arginine-
treated underfed ewes.  The third experiment determined whether administration 
of arginine could improve survival rates of lambs and enhance fetal growth in 
ewes carrying multiple fetuses.  Between Days 100 and 121 of pregnancy, ewes 
received an intravenous infusion of either saline solution (n= 14) or L-arginine-
HCl solution (345 mol of arginine/kg body weight, n=20) three times daily.  
Parenteral administration of arginine increased the percentage of lambs born 
alive and enhanced the birth weights of quadruplets.  Collectively, these results 
indicate that 1) parenteral administration of arginine improves pregnancy 
outcomes in underfed and prolific ewes; and 2) the use of arginine or citrulline 
may have important implications for the design of an effective treatment for 
preventing or ameliorating IUGR in mammals. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
Fetal growth is a complex and dynamic process that is characterized by 
an orchestrated regulation of cell proliferation, organization, and differentiation 
(Redmer et al., 2004; Ergaz et al., 2005).  It depends on the interaction between 
genes, nutrition and uterine environment which can affect uterine capacity, the 
maternal–placental–fetal unit, and the hormonal fetal and maternal milieu (Wu et 
al., 2004a; Eleftheriades et al., 2006; Gicquel & Le Bouc, 2006).  When 
metabolic insults or functional disturbances are present during fetal 
development, severe alterations in the growth trajectory of the fetus may occur, 
with consequences that can have an effect throughout the life of the individual 
(Schroder, 2003; Sizonenko et al., 2006; Wu et al., 2006; Mari & Hanif, 2007).  
Indeed, many animal studies and human epidemiological findings indicate an 
association between impaired growth in utero and increased perinatal morbidity 
and mortality, as well as with metabolic and physiological abnormalities later in 
life (Barker & Clark, 1997; Symonds et al., 2001; Ozanne & Hales, 2002; Ergaz 
et al., 2005; Fowden et al., 2006b).  
Intrauterine growth restriction (IUGR) represents nearly 11% of all live-
born infants worldwide and is therefore a condition of immense clinical and 
economic importance in human health (Ergaz et al., 2005; Murphy et al., 2006).  
In addition, it is a major concern in animal sciences, where production, 
efficiency, and performance of domestic species can be severely compromised 
(Wu et al., 2006).  However, the pathophysiological processes underlying this 
disorder are complex and incompletely understood (Ergaz et al., 2005; Wu et al., 
2006). 
____________ 
This dissertation follows the style of Journal of Physiology. 
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Abnormalities of placental development and function result in impaired 
fetal growth (Ott et al., 1997; Resnik, 2002; Chaddhaa et al., 2004; Wu et al., 
2006; Karowicz-Bilinska et al., 2007); and a reduction in fetoplacental blood flow  
has been associated with IUGR and fetal survival (Reynolds & Redmer, 1995; 
Sooranna et al., 1995; Sheppard et al., 2001; Lang et al., 2003; Wallace et al., 
2005).  In effect, the factors that regulate placental vascular formation and 
function throughout pregnancy impact blood flow, which is critical to 
transplacental exchange and nutrient transport, thereby influencing growth and 
development of the fetus (Sheppard et al., 2001; Mayhew, 2002; Kwon et al., 
2004b; Reynolds et al., 2006). 
Arginine, a nutritionally essential amino acid for the fetus (Wu et al., 
2004b), is a precursor for the synthesis of nitric oxide (NO) and polyamines in 
cells  (Wu & Morris, 1998).  Nitric oxide is a key mediator of vasodilation and 
placental angiogenesis, thus exerting an important role in the regulation of 
fetoplacental blood flow during pregnancy (Reynolds & Redmer, 2001; Kwon et 
al., 2004b; Vonnahme et al., 2005).  In addition, polyamines are key regulators 
of DNA and protein synthesis, which are crucial to the growth and proliferation of 
mammalian cells (Wu & Morris, 1998; Igarashi & Kashiwagi, 2000; Zhao et al., 
2008).  Nitric oxide biosynthesis is augmented during gestation in rats and 
sheep (Sladek et al., 1997) and increases in NO synthesis by the placenta are 
associated with an enhanced fetal growth in ewes during late gestation (Kwon et 
al., 2004b).  Interestingly, decreased concentrations of arginine and polyamines 
occur at day 78 of pregnancy in undernourished sheep (Kwon et al., 2004a) and 
inhibition of polyamine synthesis reduces placental weight and impairs fetal 
growth in rats (Ishida et al., 2002).  Conversely, there is evidence that short-term 
fetal arginine infusion in an ovine model of IUGR by placental embolization 
stimulates protein accretion by the fetus (De Boo et al., 2005).  In addition, 
enteral administration of arginine to gilts between days 30 and 114 of gestation 
increased the number of live-born piglets per litter (Mateo et al., 2007).  
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Furthermore, enteral or parenteral administration of arginine improved utero-
placental circulation and ameliorated fetal growth restriction in women (Neri et 
al., 1996; Lampariello et al., 1997; Di Renzo et al., 2005; Xiao & Li, 2005).  
Hence, modulation of the arginine-NO and polyamine pathways may play an 
important role in optimizing placental function and fetal growth and development.  
However, little is known about arginine metabolism in pregnant ewes and 
fetuses. 
Because circulatory and transport systems in the sheep placenta are 
similar to those in the human placenta, the pregnant sheep offers a valuable 
model to elucidate the mechanisms underlying IUGR (Schroder, 2003; Wallace 
et al., 2005).  Thus, the objectives of this work were to i) determine the 
pharmacokinetics of arginine and citrulline (a neutral amino acid that can be 
utilized for arginine synthesis in cells) (Wu & Morris, 1998) in maternal 
circulation, as well as arginine availability in the fetus following administration of 
either amino acid to the ewe; and ii) assess if intravenous administration of 
arginine during mid- to late-gestation ameliorates or prevents fetal growth 
retardation in sheep.  The knowledge generated from this research will help to 
lay a framework for studying cellular and molecular mechanisms responsible for 
the beneficial effects of arginine in regulating growth and development of the 
conceptus, as well as for the design of therapeutic interventions for the 
treatment and prevention of IUGR in mammals. 
 
Impact of arginine on homeostasis and pregnancy 
 
Main functions of arginine in whole body homeostasis 
Arginine is required by immature mammals for adequate growth (Mertz et 
al., 1952; Ha et al., 1978; Wu et al., 1997).  This amino acid is also needed by all 
young and adult mammals for maintenance of normal intermediary metabolism, 
including detoxification of ammonia via hepatic and intestinal urea cycles (Wu & 
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Morris, 1998).  Therefore, arginine plays an important role in preserving whole-
body homeostasis in mother and fetus during pregnancy (Wu et al., 2004a).  
Indeed, arginine is a metabolically versatile amino acid in animals, serving as a 
substrate for protein synthesis and regulating the metabolism of energy 
substrates (Beaumier et al., 1996; Wu & Morris, 1998; Wu et al., 1999; Morris, 
2002).  In addition, arginine can stimulate the secretion of important metabolic 
hormones such as insulin, GH, prolactin and glucagon, and is also able to 
activate nutrient-sensitive signaling pathways such as the mammalian target of 
rapamycin in skeletal muscle and small intestine (McAtee & Trenkle, 1971; 
Davis, 1972; Kuhara et al., 1991; Morris, 2002; Thureen et al., 2002; Meijer & 
Dubbelhuis, 2004; Wu et al., 2007a).  Moreover, arginine is the precursor of 
biologically important molecules, such as creatine, agmatine, NO, polyamines, 
proline, ornithine, citrulline and glutamate (Wu & Morris, 1998).   
Arginine can be catabolized by multiple pathways.  The enzymes that 
initiate arginine degradation are arginine:glycine amidinotransferase, arginine 
decarboxylase, arginases, and nitric oxide synthases (NOS).  With the exception 
of arginine decarboxylase, all these enzymes act on the guanidino group of 
arginine (Morris, 2004).  Arginine:glycine amidinotransferase catalyzes the first 
and rate-controlling step in the synthesis of creatine (Morris, 2004), which 
involves the metabolic cooperation of kidney, liver and muscle (Beaumier et al., 
1996).  Creatine plays a major role in energy metabolism in skeletal muscle and 
neuronal cells, where it serves as a storage form of high energy phosphate 
(Beaumier et al., 1996; Wu & Morris, 1998). 
Arginine decarboxylase converts arginine to CO2 and agmatine (Morris, 
2002), which occurs in brain and kidney.  Agmatine is a non-catecholamine 
ligand at 2-adrenergic receptors that may act as a neurotransmitter (Li et al., 
1994). 
There are two arginase isoforms: cytosolic (type I) and mitochondrial 
(type II).  Type I arginase is present primarily in hepatocytes and to a much 
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lesser extent in small intestine, mammary tissue, and certain placentae.  Type II 
arginase is expressed in most extrahepatic cells and tissues.  Arginases play an 
important role in glutamate and proline synthesis via ornithine production (Wu & 
Morris, 1998).  Glutamate, which is also synthesized from glutamine, proline and 
branched-chain amino acids, is an excitatory neurotransmitter that can give rise 
to yet another cell-signaling molecule: -aminobutyric acid (GABA) (Wu & 
Morris, 1998).  Proline plus its derivative hydroxyproline constitutes one third of 
amino acids in collagen, therefore playing important roles in wound healing, 
chronic inflammatory diseases, and infection (Beaumier et al., 1996; Morris, 
2004).  Ornithine serves as the precursor for biosynthesis of polyamines, which 
are aliphatic cations that can regulate gene expression, signal transduction, ion 
channel function, DNA and protein synthesis, apoptosis, as well as cell 
proliferation and differentiation (Thomas & Thomas, 2001; Flynn et al., 2002; 
Zhao et al., 2008).  A rate-controlling step in the synthesis of polyamines from 
ornithine is catalyzed by ornithine decarboxylase (Zhao et al., 2008).  Ornithine 
is also required for ammonia detoxification via the hepatic urea cycle (Meijer et 
al., 1990) and proline synthesis via ornithine aminotransferase. 
The NOS has three isoforms that were named after the cell type from 
which they were first isolated.  Endothelial NOS and neuronal NOS are 
constitutively expressed in different cells and their activity is regulated by the 
Ca++/calmodulin complex.  A third NOS isoform is inducible and requires a delay 
of 6–8 h before the onset of NO production but, once induced, produces large 
quantities of NO for hours to days in a calcium-independent manner (Wu & 
Morris, 1998; Beck et al., 1999).  Catabolism of arginine by NOS results in the 
release of NO and citrulline.  Nitric oxide is a free radical that functions as a 
major mediator of numerous biological processes, including vasodilation, 
immune responses and neurotransmission (Wu & Meininger, 2002; Maul et al., 
2003).  Citrulline is a key intermediate in the urea cycle and an efficient 
antioxidant protecting DNA, lipids and proteins from hydroxyl radical-induced 
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oxidative damage (Akashi et al., 2001).  Although citrulline is not a precursor for 
tissue protein synthesis, it can be effectively recycled to arginine, because of the 
widespread presence of argininosuccinate synthase and argininosuccinate lyase 
in tissues (Wu & Morris, 1998). 
Arginine requirements in most mammalian cells are met primarily by 
uptake of extracellular arginine via specific transporters.  An important 
transporter is the high-affinity, Na+-independent system y+ (Wu & Morris, 1998).  
Because of its major role in arginine transport, regulation of system-y+ 
expression or activity represents a potential target for modulating cellular 
arginine metabolism (Wu & Morris, 1998). Other cationic amino acids and 
positively charged analogues are effective inhibitors of arginine uptake by 
system y+ (Wu & Morris, 1998). 
 
Arginine abundance in the conceptus 
Arginine is one of the most abundant amino acids deposited in fetal tissue 
proteins (Meier et al., 1981; Wu et al., 1999).  In fact, the relative amounts of 
arginine in tissue mixed proteins range from 5% to 15% (Silk et al., 1985; Davis 
et al., 1993), indicating the quantitative importance of arginine in fetal growth.  In 
addition, concentrations of arginine and of other biomolecules linked to arginine 
metabolism change dynamically in fetal fluids during gestation, which can affect 
fetal and placental development (Wu et al., 1999; Kwon et al., 2003a; Kwon et 
al., 2003b; Kwon et al., 2004b).  Notably, arginine and citrulline are unusually 
abundant in porcine and ovine allantoic fluids, respectively, during early 
gestation (Wu et al., 1995; Wu et al., 1996; Kwon et al., 2003a).  Interestingly, 
arginase is absent from porcine placenta, therefore maximizing the transfer of 
arginine from maternal to fetal plasma and the abundance of arginine in porcine 
allantoic fluid. Conversely, arginase activity is present in ovine placenta and 
allantoic fluid, thus the high concentrations of citrulline could reflect an 
adaptation of the ovine fetus to maintain an efficient reservoir of an arginine 
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precursor (Kwon et al., 2003a).  Hence, it appears that different strategies can 
be used by different animal species to conserve arginine during this stage of 
pregnancy (Kwon et al., 2003a).  Moreover, increased activities of 
argininosuccinate synthase and argininosuccinate lyase at Day 60 of gestation 
were associated with increased arginine concentration in ovine allantoic fluid 
between Days 40 and 60 of gestation (Kwon et al., 2003a).  In addition, arginase 
and ornithine decarboxylase activities were elevated on Day 40 of gestation in 
placental and endometrial tissues of sheep (Kwon et al., 2003b).  Accordingly, 
concentrations of ornithine increased and supported high rates of polyamine 
synthesis (Kwon et al., 2003b).  Notably, all these changes occurred during a 
stage of maximal placental growth (Alexander, 1964; Reynolds & Redmer, 
1995).  Furthermore, relatively high levels of polyamine concentrations were 
present in ovine placental and endometrial tissues in the second half of 
pregnancy (Kwon et al., 2003b), when there is continued development of the 
placental vascular bed and increases in total uterine blood flow (Ford, 1995; 
Reynolds & Redmer, 1995, 2001).  This vascular adaptation plays an important 
role in enhancing the transfer of nutrients and oxygen from maternal to fetal 
blood to support the phase of most rapid absolute growth of the fetus in late 
gestation.  Moreover, maximal activities of NOS, and highest rate of NO 
synthesis occurred in ovine placenta and endometrium in the first half of 
pregnancy (Sooranna et al., 1995; Kwon et al., 2004b), exhibiting a second peak 
during late gestation (Zheng et al., 2000; Sheppard et al., 2001; Kwon et al., 
2004b).  Hence, it appears that metabolic coordination through different 
integrated pathways allows increased arginine availability during crucial stages 
in growth and development of the conceptus. 
 
Functions of arginine in the establishment and maintenance of pregnancy 
Studies in the past fifteen years have linked the arginine-NO and 
polyamines pathways to crucial events for the establishment and maintenance of 
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mammalian pregnancy, including early embryo development, implantation, 
growth and vascularization of the placenta and possibly uterine quiescence and 
cervical ripening (Henningsson et al., 1983; Sooranna et al., 1995; Gregg, 2003; 
Kwon et al., 2003b; Kwon et al., 2004b; Wu et al., 2006; Zhao et al., 2008).  
Translation of this basic knowledge into clinical practice or animal production 
has received increasing interest. 
 
Early embryonic development and implantation.  Studies conducted in murine 
embryos have shown that normal in vitro development required NO production 
by the embryo itself, and that an inhibition of NO synthesis, accomplished by 
addition of NOS inhibitors to the culture media, arrested embryo development 
(Gouge et al., 1998; Chen et al., 2001).  Moreover, impairment of embryo 
development produced by the lack of NO could be reversed by the addition of an 
NO donor (Tranguch et al., 2003).  However, as an oxidant, a high concentration 
of NO can be detrimental for the embryo (Tranguch et al., 2003).  The presence 
of mRNA for all three NOS isoforms in preimplantation embryos of rodents 
provided further evidence for the importance of NO production in the embryo 
(Gouge et al., 1998; Tranguch et al., 2003).  In addition, pre-implantation stage 
rhesus monkey blastocysts expressed the inducible form of NOS, while 
cytotrophoblast cells lining the embryonic cavity expressed both endothelial and 
inducible forms of NOS at distinct stages of placentation (Sengupta et al., 2005).  
Furthermore, a pilot study with humans showed that increased NO production, 
measured indirectly through mean nitrite/nitrate concentrations in culture media, 
was positively associated with the growth potential of a developing embryo 
(Battaglia et al., 2003).   
Although the molecular mechanisms for NO in regulation of embryo 
development and survival remain unclear, the cGMP pathway was involved in 
the signal transduction of NO-regulated embryo development but not in embryo 
apoptosis induced by high concentrations of NO (Chen et al., 2001). 
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Nitric oxide also participates in modulating vascular changes that 
accompany trophoblast implantation, which appears to be regulated by an 
interaction of NO with estrogen and progesterone (Gouge et al., 1998; Chwalisz 
et al., 1999 ; Sengoku et al., 2001 ; Maul et al., 2003) and mediated by cGMP 
(Duran-Reyes et al., 1999).  High NOS activities have been observed in the 
connective tissue surrounding spiral arterioles in the endometrium and the 
implantation site in baboon and mice, respectively, during implantation (Purcell 
et al., 1999a; Purcell et al., 1999b).  Also, invading trophoblast cells co-
expressing the endothelial and inducible NOS forms caused dilatation of utero-
placental arteries in guinea pigs, suggesting that NO mediates spiral arterial 
changes occurring during pregnancy (Nanaev et al., 1995 ). 
An additional mode of action of NO in implantation might involve induction 
of matrix-degrading proteases, resulting in remodeling of the extracellular matrix 
necessary for trophoblast invasion (Novaro et al., 2001).  Production of NO by 
trophoblasts and endometrial leukocytes may also contribute to the local 
modulation of maternal immunity at the peri-implantation stage (Dembinska-Kiec 
et al., 1991; Thaler & Epel, 2003). 
Polyamines also participate in embryo development and implantation.  
Studies in mice show that expression of ornithine decarboxylase in the 
subluminal uterine stroma was dependent upon the presence of an active 
blastocyst in implantation sites (Zhao et al., 2008), and homeostasis of uterine 
polyamines was important for endometrial cell proliferation (Henningsson et al., 
1983; Zhao et al., 2008).  In addition, an immunosuppressive role for polyamines 
during early pregnancy has also been proposed (Sooranna et al., 1995).  
Moreover, polyamines are required at different phases of cell cycle progression, 
modulating the functions of RNA, DNA, nucleotide triphosphates, proteins and 
other acidic substances (Igarashi & Kashiwagi, 2000; Thomas & Thomas, 2001). 
Hence, polyamines seem to be essential for embryo implantation and are critical 
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for survival and development of the conceptus (Fozard et al., 1980; 
Henningsson et al., 1983; Ishida et al., 2002; Zhao et al., 2008). 
 
Growth and vascularization of the placenta.  Adequate placental growth is 
essential for adequate fetal growth (Gootwine, 2004; Murphy et al., 2006), and 
arginine, through NO and polyamines, is involved in placental development and 
function throughout gestation.  Indeed, polyamines regulate cell growth and 
proliferation in the placenta and fetus (Igarashi & Kashiwagi, 2000; Thomas & 
Thomas, 2001), whereas NO participates in the modulation of placental vascular 
growth and thus of placental blood flow (Sladek et al., 1997; Reynolds & 
Redmer, 2001; Bird et al., 2003).  Indeed, a positive correlation exists between 
placental size and function and birth weight (Resnik, 2002; Luther et al., 2005; 
Regnault et al., 2005a; Bryan & Hindmarsh, 2006).  Hence, remodeling of the 
placenta, including growth and development of the vascular bed, is essential to 
normal placental function, therefore impacting the transfer of nutrients and O2 
from the mother to the fetus and supporting fetal growth (Mayhew, 2002; Lang et 
al., 2003; Reynolds et al., 2005a).  Certainly, IUGR has been associated with 
reduced fetoplacental blood flow (Sooranna et al., 1995; Chaddhaa et al., 2004).  
Furthermore, uniform restriction of uterine blood flow by the use of adjustable 
vascular occluders, without primary placental insults, led to changes in the 
growth pattern of affected fetuses and placentae (Lang et al., 2000).  In addition, 
placental expression of angiogenic factors was reduced in nutrient-restricted and 
overnourished ewes (Redmer et al., 2005; Reynolds et al., 2005a).  Similarly, 
placental angiogenesis was altered in other ovine models of compromised 
pregnancy, including thermal stress, hypobaric conditions, and multiple fetuses 
(Reynolds et al., 2005a; Murphy et al., 2006).   
The increase in utero-placental blood flows with advancing pregnancy 
results from vasodilation and angiogenesis as the placenta continues to remodel 
(Reynolds & Redmer, 2001; Sheppard et al., 2001; Lang et al., 2003; Vonnahme 
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et al., 2005).  Both placental and uterine tissues from pregnant sheep produce 
NO as well as polyamines in patterns that coincide with the periods of most rapid 
placental and fetal growth (Zheng et al., 2000; Kwon et al., 2003b; Kwon et al., 
2004b).  Moreover, endothelial NOS expression is increased in uterine arteries 
during late pregnancy in sheep (Zheng et al., 2000; Sheppard et al., 2001), and 
inhibition of NOS resulted in the ipsilateral reduction of uterine blood flow without 
altering flow in the contralateral uterine artery or changing maternal systemic 
blood pressure (Miller et al., 1999).  These results suggest that endogenously 
produced NO in the uterine vasculature of late-pregnant ewes contributes to 
basal maternal vasodilator tone.  In support of this view, intramuscular 
administration of sildenafil citrate, a vasodilator that enhances the effect of NO 
by inhibiting phosphodiesterase type 5, from gestational days 28 to 112 was 
effective to increase fetal growth in both underfed and adequately nourished 
ewes (Satterfield et al., 2007).  In effect, impaired placental syntheses of NO and 
polyamines has been proposed as a unified explanation for IUGR in response to 
nutritional problems such as under- or over- feeding (Wu et al., 2004a).  
Exogenous administration of arginine is an effective means of increasing 
endogenous NO synthesis (Wu and Meininger, 2002).  In fact, arginine 
supplementation has been shown to improve uteroplacental circulation and 
infant weight at birth in women presenting IUGR (Lampariello et al., 1997; Di 
Renzo et al., 2005; Xiao & Li, 2005).  In addition, dietary arginine provision has 
resulted in enhanced litter size in gilts (Mateo et al., 2007) and rats (Zeng et al., 
2008). 
Mediation of angiogenesis by NO may occur by triggering and 
transducing cell growth and differentiation via NOS activation, cGMP elevation, 
mitogen activated kinase (MAPK) activation, and fibroblast growth factor-2 
(FGF-2) expression (Ziche & Morbidelli, 2000; Zheng et al., 2006).  In addition, 
NO can regulate the expression of other angiogenic factors such as VEGF 
(Reynolds & Redmer, 2001; Maul et al., 2003).  Furthermore, in the 
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endometrium, NO may interact with platelet-activating factor, a potent 
inflammatory lipid mediator that is known to increase vascular permeability and 
vasodilatation (Ahmed et al., 1998).  Regulation of expression of 
metalloproteases and their tissue inhibitors by NO also contributes to the 
degradative capacity of endothelial cells that correlates with matrix invasion 
during angiogenesis (Ziche & Morbidelli, 2000). 
 
Uterine quiescence and cervical ripening.  Some studies suggest that NO may 
have a role in the complex control system that maintains uterine quiescence 
during pregnancy (Izumi et al., 1993; Ramsay et al., 1996; Sladek et al., 1997; 
Norman et al., 1999; Gregg, 2003); as well as in cervical ripening at term (Maul 
et al., 2003; De Pace et al., 2007). Indeed, all three NOS isoforms have been 
found in myometrial and cervical tissues from various species, including humans 
(Izumi et al., 1993; Sladek et al., 1997; Norman et al., 1999), and inhibition of 
NO synthesis causes preterm delivery in the mouse (Tiboni & Giampietro, 2000).  
Notably, while the NO system seems to be up-regulated in the myometrium 
during pregnancy, the opposite occurs in the cervix, and these conditions are 
reversed at term (Buhimschi et al., 1996; Maul et al., 2003). In addition, the 
myometrium and cervix have a differential temporo-spatial expression of the 
NOS isoforms (Bansal et al., 1997; Dong et al., 1998; Norman et al., 1999; Maul 
et al., 2003). 
Despite functional and molecular studies, the exact role of the NO system 
in the control of myometrial function during pregnancy has not yet been clearly 
defined (Tiboni & Giampietro, 2000).  Nonetheless, it appears likely that NO acts 
in concert with progesterone affecting the cGMP pathway, as well as other 
systems such as direct effects on ion handling by the muscle (Buhimschi et al., 
1996; Chwalisz & Garfield, 1998; Maul et al., 2003).  As for cervical ripening, NO 
may act in cooperation with other biomolecules of the inflammatory cascade, 
such as prostaglandins and COX, to induce local vasodilation and increase 
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vascular permeability and leukocyte infiltration (Chwalisz & Garfield, 1998; Maul 
et al., 2003). In addition, NO may regulate metalloproteases that allow for the 
rearrangement of collagen fibers (Chwalisz & Garfield, 1998; Maul et al., 2003).  
However, further investigation is needed to fully understand the biochemical 
processes involved (Sladek et al., 1997; Norman et al., 1999; Maul et al., 2003). 
 
Intrauterine growth restriction 
Growth of the fetus depends on multiple biological and environmental 
factors (Wu et al., 2004a; Eleftheriades et al., 2006; Gicquel & Le Bouc, 2006).  
Intrauterine growth restriction can be defined as a deviation from an expected 
pattern of fetal growth that leads to attenuation of fetal growth potential due to an 
insult that has occurred in utero (Ergaz et al., 2005; Wu et al., 2006).  Further, 
IUGR may be classified clinically on the basis of a birth weight below the tenth 
percentile for gestational age in infants, relative to the reference population 
(McMillen et al., 2001).  In fact, assessment of fetal growth currently constitutes 
an essential issue for prenatal surveillance in human medicine (Gardosi, 1997).  
Certainly, growth aberration is one of the main manifestations of abnormal 
intrauterine development (Barr et al., 1994).  Moreover, the growth trajectory of 
the fetus and its adaptive responses to the prenatal and postnatal environment 
may be determined beginning from the period around conception and continuing 
throughout gestation (Ergaz et al., 2005; Myatt, 2006; Valsamakis et al., 2006).  
In fact, an IUGR fetus can be further classified as symmetric or asymmetric 
according to the onset of the causative fetal insult (Resnik, 2002; Monk & Moore, 
2004; Ergaz et al., 2005).  Symmetric IUGR fetuses are often exposed to 
intrauterine insults early in gestation, with a generalized decrease in cell division 
and cell growth that results in a proportionate reduction of fetal measurements. 
Conversely, asymmetric IUGR fetuses suffer an adverse environment later in 
intrauterine life, undergoing a disproportionate growth because normal growth of 
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vital organs such as the brain is usually maintained (Resnik, 2002; Valsamakis 
et al., 2006).  
The etiology of IUGR could be multifactorial, involving both genetic and 
environmental factors to a varying degree (Monk & Moore, 2004).  Several 
maternal, fetal and uteroplacental factors can be related with perturbation of fetal 
growth.  These factors include maternal age, nutrient intake, hypoxia, health, 
smoking and alcohol or drug abuse; fetal disruption of gene expression, 
chromosomal abnormalities, as well as fetal number; and placental hormone 
production, nutrient transport capacity and vascularity (Bajoria et al., 2001; 
Cetin, 2003; Monk & Moore, 2004; Dunger et al., 2006; Fowden et al., 2006a; 
Murphy et al., 2006; Wu et al., 2006; Gootwine et al., 2007).  However, the 
specific pathophysiological processes underlying IUGR are complex and 
incompletely understood (Ergaz et al., 2005; Wu et al., 2006).  Nevertheless, 
growing evidence suggests that, independent of the predisposing factor(s), 
impaired fetal growth is frequently associated with abnormalities of placental 
development and function (Lang et al., 2003; Lea et al., 2005; Luther et al., 
2005; Reynolds et al., 2005a; Wallace et al., 2005; Murphy et al., 2006; Wu et 
al., 2006).  Indeed, both genetic and environmental factors can disrupt placental 
development, having an impact on placental vascularity and uteroplacental 
blood flows, which ultimately determines placental sufficiency (Vonnahme et al., 
2003; Redmer et al., 2004; Wu et al., 2004a; Regnault et al., 2005b; Fowden et 
al., 2006a; Gluckman & Hanson, 2006; Wu et al., 2006).  
 
Focal aspects of normal placental vascular development 
In mammalian species, placental growth occurs predominantly in the first 
half of pregnancy, but continues to undergo morphological, structural and 
biochemical changes throughout gestation to ensure that placental function 
parallels fetal growth (Mellor, 1983; Owens, 1991; Ford, 1995; Reynolds et al., 
2006).  In fact, disruption of the normal pattern of placental development will 
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lead to a placenta with an altered function (Chaddha et al., 2004; Myatt, 2006).  
One of the factors that plays a central role in adequate placental function is 
nutrient transfer capacity of the placenta, which directly influences the growth 
trajectory of the fetus and hence weight at birth (Reynolds & Redmer, 1995; 
Redmer et al., 2004).  Transplacental exchange is largely dependent upon 
uterine and umbilical blood flows, and these blood flows are in turn dependent 
on adequate vascularization of the placenta (Lang et al., 2000; Myatt, 2006; 
Reynolds et al., 2006; Luther et al., 2007).  Indeed, utero-placental vasculature 
undergoes adaptive changes throughout gestation that include vasculogenesis, 
angiogenesis and vasodilation, as well as an increase in vascular permeability 
(Reynolds & Redmer, 1995; Myatt, 2006).  Vasculogenesis is the process of 
forming a primitive vascular network through endothelial progenitor cells, and 
angiogenesis represents the development of new vessels from pre-existing ones 
(Zygmunt et al., 2003).  Actually, vasculogenesis can first be observed at the 
stage of early tertiary villi in human placentae (Asan et al., 1999), and 
morphological studies using microscopical sections at different periods of 
gestation confirmed that angiogenesis is linked to villous growth and maturation 
(Mayhew, 2002). 
Placental vascular growth begins as early as 21 days after conception 
and continues throughout gestation in humans (Asan et al., 1999).  Certainly, 
dramatic changes in the vascular content and arrangement, characterized by 
disproportionate growth and expansion of villous arborizations, occur between 
the end of the first trimester (10-13 weeks) and the last month of pregnancy (38-
41 weeks) (Mayhew, 2002).  In sheep, vascular volume of the endometrium 
exhibits a two-fold increase in the gravid uterine horn by day 24 after mating 
(Reynolds & Redmer, 1992).  In addition, capillary area density of both maternal 
caruncular and fetal cotyledonary tissues increased exponentially from day 50 
through day 140 after mating (Reynolds et al., 2005b).  Accordingly, the increase 
of uterine and umbilical blood flows is most remarkable from mid to late 
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gestation (Rosenfeld et al., 1974; Fuller et al., 1975), coinciding with the period 
of maximal fetal growth (Redmer et al., 2004; Gootwine et al., 2007).  In fact, it is 
estimated that by the end of gestation, 20% of the maternal cardiac output is 
targeted to the uterus to support fetal growth in sheep (Gootwine et al., 2007). 
The placenta is a rich source of angiogenic factors that may play an 
important role in the regulation of placental vessel formation, as well as in 
maternal vascular adaptation to pregnancy (Reynolds & Redmer, 2001; Zygmunt 
et al., 2003).  Expression of VEGF, FGF, angiopoietins and their receptors, as 
well as endothelial NO synthase, has been described in different mammalian 
species, including humans (Geva & Jaffe, 2000; Zheng et al., 2000; Reynolds & 
Redmer, 2001; Wulff et al., 2003; Reynolds et al., 2005b; Vonnahme et al., 
2005; Borowicz et al., 2007; Luther et al., 2007).  Interestingly, expression of 
angiogenic factors can be altered in compromised pregnancies, including those 
resulting from maternal undernutrition or overnutrition and pre-eclampsia 
(Rutherford et al., 1995; Cooper et al., 1996; Brennecke et al., 1997; Wu et al., 
1998a; Redmer et al., 2005; Reynolds et al., 2005b; Luther et al., 2007). 
 
Fetal growth restriction, physiologic adaptations and postnatal 
development 
Low birth weight is associated with an increased risk of neonatal mortality 
and morbidity (Mellor, 1983; McIntire et al., 1999; Resnik, 2002; Van Rens et al., 
2005).  Findings from both animal and human studies indicate that IUGR 
neonates frequently present complications such as hypoxia, hypoglycemia and 
oxidative stress, have a diminished capacity to withstand thermoregulatory 
challenges soon after birth, and are likely to develop pulmonary, digestive and 
circulatory disorders (Resnik, 2002; Greenwood & Bell, 2003; Monk & Moore, 
2004; Wu et al., 2004a).  Furthermore, there is a higher incidence of premature 
deliveries among fetuses that are growth restricted (Cook et al., 1988; Fliegner, 
1989; Bryan & Hindmarsh, 2006; Siddiqui & McEwan, 2007), with approximately 
  
17 
5% of all IUGR infants being born before term (Bryan & Hindmarsh, 2006).  
Consequently, IUGR is associated with considerable financial and emotional 
costs both in medical and agricultural sectors (Ergaz et al., 2005; Luther et al., 
2005; Wu et al., 2006). 
Experimentally, the metabolic, physiological and functional abnormalities 
seen in individuals that suffered IUGR may be linked to the physiological 
adaptations that the growth-retarded fetus suffers in response to a suboptimal 
intrauterine environment, which can be of critical importance not only for 
perinatal health and survival but also for longer term health outcome (Barker & 
Clark, 1997; McMillen et al., 2001; Luther et al., 2005).  Indeed, the timing, 
nature and intensity of the uterine insults can differentially impact the individual, 
affecting development and function of organs, tissues and systems with varying 
severity (McMillen et al., 2001; Resnik, 2002; Greenwood & Bell, 2003).  For 
instance, premature birth of IUGR fetuses has been associated with an 
accelerated maturation of the hypothalamic-pituitary-adrenal (HPA) axis, that 
may result in altered concentrations of ACTH and glucocorticoids during late 
pregnancy (Economides et al., 1988; Phillips et al., 1996; Edwards & McMillen, 
2002; Bloomfield et al., 2004; Kumarasamy et al., 2005).  In fact, concentrations 
of glucocorticoids in the growth-restricted fetus may be partly modulated by the 
enzyme 11-hydroxysteroid dehydrogenase (11-HSD), because restriction of 
placental growth resulted in a twofold increase in 11-HSD mRNA expression in 
the liver of IUGR sheep fetuses in late gestation (McMillen et al., 2000).  Further, 
the increase in intrahepatic 11-HSD may play a role in glucocorticoid-mediated 
increases in glycogen deposition and gluconeogenesis in the liver that occur 
immediately before birth and which could be critical for perinatal survival after a 
period of substrate deprivation (McMillen et al., 2001).  Additionally, it has been 
proposed that elevated or decreased cortisol concentrations in adults that were 
once IUGR fetuses may occur as a consequence of in utero adaptations of the 
HPA axis, possibly altering neuroendocrine response to stressors throughout 
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lifetime (Edwards & McMillen, 2002; Kajantie et al., 2002; Eleftheriades et al., 
2006). 
Other metabolic and/or endocrine systems that alter functions such as 
growth, reproduction and energy metabolism may also be disturbed by 
environmental disruptions during fetal life (McMillen et al., 2001; Greenwood & 
Bell, 2003; Gardner et al., 2005; Eleftheriades et al., 2006; Sizonenko et al., 
2006).  For example, IUGR has been associated with changes in fetal amino 
acid metabolism, where urea production is reduced in the fetus during late 
gestation, increasing the risk of toxic hyperammonemia after birth (Greenwood & 
Bell, 2003; De Boo et al., 2007).  There is also evidence that fetal plasma 
concentrations of anabolic hormones such as IGF-I, insulin, prolactin and thyroid 
hormones are decreased near term in an ovine model of IUGR due to placental 
restriction (Symonds et al., 2001).  Free thyroxine and triiodothyronine 
concentrations in plasma are also reduced in IUGR human fetuses when 
compared with gestationally-matched normal fetuses (Kilby et al., 1998).  
Moreover, abundance of mRNA for the long form of the prolactin receptor in 
adipose tissue and for prolactin in the fetal pituitary are decreased in growth-
restricted ovine fetuses (Phillips et al., 2001; Symonds et al., 2001).  In addition, 
IUGR induced by maternal protein restriction throughout pregnancy and lactation 
in rats resulted in the development of diabetes, hyperinsulinemia and tissue 
insulin resistance of the offspring in adulthood (Fernandez-Twinn et al., 2003; 
Ozanne et al., 2003).  Further, the capacity of the fetal adrenal medulla to 
synthesize and secrete catecholamines is potentially impaired from mid-
gestation in placentally restricted ovine fetuses (Coulter et al., 1998), and IUGR 
rat-pups have impaired adrenaline secretory responses to acute hypoxia after 
birth (Shaul et al., 1989). 
It has been postulated that the adaptive responses that occur in the 
growth restricted fetus could result from an asymmetric redistribution of blood 
flow that distinctly influences the developmental trajectory of organs and tissues, 
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thus affecting and probably resetting their functional characteristics (Desai et al., 
1996; Hoet & Hanson, 1999; Tekay & Jouppila, 2000; Gluckman & Hanson, 
2006; Malamitsi-Puchner et al., 2006).  The sequelae of such alterations may be 
immediate or may not be clinically apparent until later in life, therefore impacting 
long term health and the onset of diseases such as type 2 diabetes, 
cardiovascular disease and hypertension (Barker & Clark, 1997; Symonds et al., 
2001; Osgerby et al., 2002; Ingelfinger, 2004 ; Gardner et al., 2007).  Indeed, 
animal models of IUGR induced by undernutrition or by placental insufficiency 
indicate that most of the fetal circulating nutrients and energy are directed to 
growth maintenance of vital organs, such as the heart and brain at the expense 
of other tissues, including liver, pancreas, muscle, bone and fat, which have 
decreased sizes and weights in growth restricted fetuses (Desai et al., 1996; 
McMillen et al., 2001; Osgerby et al., 2002; Satterfield et al., 2007).  In fact, 
evidence now suggests that even organs of primary importance such as the 
brain, which may not have an evident reduction in relative fetal mass, can be 
functionally compromised by IUGR, leading to an increased risk of neurological 
and behavioral disorders due to reduced number of neurons and long-term 
alterations in brain structure formation and function (Kilby et al., 2000; Mallard et 
al., 2000; Duncan et al., 2004; Rehn et al., 2004). 
Epigenetic processes may also modify the physiological structure and 
function of organs and systems in IUGR fetuses, by altering gene expression 
(Wu et al., 2006; Gluckman et al., 2007).  Specifically, DNA methylation and 
covalent modification of histones seem to be susceptible to environmental 
influences and are involved in the induction of an altered phenotype by 
nutritional constraint in early life (Burdge et al., 2007a).  Nutrition affects 
methylation patterns because components and cofactors needed for methylation 
reactions come from dietary methyl donors such as methionine, choline, folic 
acid and vitamin B12 (Wu et al., 2006).  Indeed, feeding a protein-restricted diet 
to pregnant rats altered gene expression by altering methylation and histone 
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modifications of the hepatic peroxisomal proliferator-activated receptor and the 
hepatic glucocorticoid receptor promoters (Lillycrop et al., 2005; Lillycrop et al., 
2007).  Further, the differential changes in the methylation of individual CpG 
dinucleotides in the hepatic peroxisomal proliferator-activated receptor alpha 
promoter that occur in juvenile rats persist in adults (Lillycrop et al., 2008).  
Moreover, epigenetic alterations resulting from intrauterine fetal adaptation to 
nutritional constraint can be passed to subsequent generations (Burdge et al., 
2007b; Godfrey et al., 2007). 
In sum, IUGR is a significant problem in both medicine and animal 
production.  Available evidence suggests that environmental insults (e.g., 
maternal undernutrition) may cause IUGR, which is associated with impairment 
of structural and functional development of the placenta and fetus.  Identifying 
effective means to prevent or ameliorate IUGR has important implications for 
both medicine and animal sciences.  One of such approaches may be 
exogenous administration of arginine, a nutritionally essential amino acid for the 
fetus that has important roles in metabolism and physiology, including vascular 
homeostasis, angiogenesis and placental growth. 
 
Objectives 
The main goal of this dissertation research was to determine if parenteral 
administration of arginine during mid- to late gestation to ovine models of IUGR 
would ameliorate or prevent fetal growth retardation.  In the first experiment, we 
hypothesized that intravenous administration of citrulline to the pregnant ewe 
would be more effective than arginine for enhancing arginine availability to the 
fetus.  The second experiment was conducted to determine if long-term maternal 
intravenous administration of arginine during pregnancy would positively affect 
weights at birth of lambs from undernourished ewes.  Finally, the third 
experiment was designed to assess if administration of arginine to late pregnant 
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mothers would enhance fetal survival and increase lamb birth weights in ewes 
carrying multiple fetuses.  
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CHAPTER II 
INTRAVENOUS ADMINISTRATION OF CITRULLINE TO PREGNANT EWES 
IS MORE EFFECTIVE THAN ARGININE TO ENHANCE ARGININE 
AVAILABILITY IN THE FETUS 
 
Introduction 
 There is increasing evidence that arginine plays an important role in 
mammalian pregnancy (Henningsson et al., 1983; Sooranna et al., 1995; Kwon 
et al., 2003b; Kwon et al., 2004b; Wu et al., 2006; Zhao et al., 2008).  Of 
particular interest, nitric oxide (NO) and polyamines  (products of arginine 
catabolism) are involved in crucial events such as implantation, embryogenesis, 
and uterine quiescence throughout gestation, and regulate vascularization, 
growth, and development of the placenta (Neri et al., 1995; Reynolds & Redmer, 
2001; Ishida et al., 2002; Bird et al., 2003; Maul et al., 2003; Zhao et al., 2008).  
As a major vasodilator, NO modulates utero-placental blood flow and the 
transfer of nutrients from mother to fetus (Bird et al., 2003). Indeed, 
administration of arginine improved uteroplacental circulation and ameliorated 
fetal growth restriction in women (Lampariello et al., 1997; Di Renzo et al., 2005; 
Xiao & Li, 2005) and dietary arginine supplementation enhanced fetal survival 
and growth in gilts (Mateo et al., 2007). 
Arginine is alkaline in physiological solutions, and therefore, to prevent an 
acid-base imbalance, its hydrochloride (HCl) salt is generally used for 
intravenous administration into animals and humans (Wu & Meininger, 2000).  
However, there are concerns over the effect of chronic provision of chloride on 
the metabolism and health of both mother and fetus.  Furthermore, the biological 
half-life of arginine in mammals is relatively short (e.g., 45 min in ewes on Day 
105 of gestation) (Wu et al., 2007a) due to arginase that degrades arginine in 
cells and tissues, including the ovine placenta (Wu & Morris, 1998; Morris, 2002; 
Kwon et al., 2004b).  An alternative approach is to use citrulline (Wu & 
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Meininger, 2000), a neutral amino acid that can be utilized for arginine synthesis 
in cells (Wu & Morris, 1998).  In addition, limited degradation of citrulline in the 
placenta would maximize its transfer from mother to fetus (Kwon et al., 2003a; 
Wu et al., 2008). 
We hypothesized that intravenous administration of citrulline to pregnant 
dams would be more effective than arginine for enhancing arginine availability to 
the fetus.  This hypothesis was tested in gestating ewes, an established valuable 
model for studying human fetal growth (Bird et al., 2003; Schroder, 2003), by 
determining the pharmacokinetics of arginine and citrullline in maternal plasma, 
as well as arginine availability in the fetus, in response to intravenous 
administration of either amino acid to the ewe.   
 
Materials and methods 
Ewes 
Six multiparous Suffolk crossbred ewes with a body weight of 62.4 ± 3.2 
kg (mean ± SEM) were used for catheterization of maternal and fetal blood 
vessels.  Animals were sheared, washed and confined in individual pens indoors 
with free access to drinking water and fed at 0700h and 1800h to meet 100% of 
the NRC (National Research Council, 1985) nutrient requirements for pregnant 
sheep.  A complete pelleted diet (Table 2.1) was purchased from Producers 
Cooperative Association (Bryan, TX, USA).  Ewes consumed all of the feed (22 
g/kg body weight) provided daily.  This study was approved by the Texas A&M 
University Institutional Animal Care and Use Committee. 
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Table 2.1. Exp. 1/ Composition of the diet (as-fed basis)1 
 Ingredients 
 
Content 
Wheat midds  37.79% 
Corn  20% 
Dehydrated alfalfa  15% 
Soybean hulls  12% 
Soybean meal  5.25% 
Rice bran  5% 
Liquid binder  2.5% 
Ground limestone  1.42% 
Ammonium chloride  0.50% 
Mineral mixture  0.30% 
Vitamin mixture  0.05% 
 
1Provided the following in the diet: 15% crude protein; 4.09% crude fat; 11.81% crude fiber; 1.0% 
calcium; 0.55% phosphorus; 0.60% chlorine; 0.20% sodium; 1.13% potassium; 0.18% sulfur; 
0.27% magnesium; 174 ppm manganese; 187 ppm iron; 13.3 ppm copper; 0.31 ppm cobalt; 150 
ppm zinc; 1.01 ppm iodine; 0.56 ppm selenium; 1.00 ppm molybdenum; 13,451 IU/kg vitamin A; 
15.6 IU/kg vitamin E; 1.76 mg/kg thiamin; and 0.27 mg/kg vitamin K. 
 
 
 
Surgical instrumentation and experimental design 
After a 7-day period of acclimation to their confinement conditions and 
coinciding with gestational day 130 ± 1 (mean ± SEM), ewes were instrumented 
with catheters to access maternal and fetal vessels as previously described 
(Cudd et al., 2001). Briefly, anesthesia was induced by intravenous 
administration of diazepam (0.2 mg/kg, Abbott Laboratories, North Chicago, IL, 
USA) and ketamine (4 mg/kg, Fort Dodge, IA, USA).  A surgical plane of 
anesthesia was maintained using isofluorane (0.5%-2.5%, Abbott Laboratories, 
North Chicago, IL, USA) after endotracheal intubation.  The ewes were 
positioned in dorsal recumbency and a ventral midline laparotomy was 
performed to expose uterus and fetal membranes which were incised.  After 
exteriorizing a hind leg of the fetus, a polyvinyl chloride catheter (0.08 cm inner 
diameter, 0.13 cm outer diameter) was passed from the cranial tibial artery into 
the femoral artery.  The procedure was repeated for the alternate leg, after 
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which the fetus was returned to the amniotic sac, and the uterus was closed with 
sutures prior to closing the maternal midline incision.  The ewes were then 
instrumented to access arterial and venous circulation by advancing polyvinyl 
chloride catheters (0.13 cm inner diameter, 0.23 cm outer diameter) into the 
maternal aorta and vena cava via the femoral artery and vein, respectively.  
Fetal and maternal catheters were passed through the abdominal wall in the 
flank of the ewe and secured in a pouch attached to the skin. 
Following post-surgical recovery for 5 days, all ewes received a sterile 
intravenous bolus dose of L-arginine-HCl (Sigma-Aldrich Corp.) equivalent to 
155 µmol L-arginine/kg body weight on the first day of sampling (Day 1) or the 
same dose of L-citrulline (Sigma-Aldrich Corp.) on the subsequent day (Day 2).  
A previous study from our laboratory showed that arginine was completely 
cleared from the circulation at 5 h after its intravenous administration to pregnant 
ewes (Wu et al., 2007a).  Infused solutions were prepared at a concentration of 
1.5 g of arginine per 5 ml or 1.5 g of citrulline per 20 ml, using sterile physiologic 
saline (0.9% sodium chloride, Hospira Inc., Lake Forest, IL, USA).  After 
adjusting the pH to 7.0 with 1 M NaOH, solutions were filtered through a 0.22-
m cellulose acetate filter (Corning Inc., NY, USA) into sterile glass containers 
fitted with sterile rubber caps.  The total volumes of the arginine-HCl or citrulline 
solution administered to a ewe were approximately 6.0 and 22.5 ml, 
respectively.  On both treatment days, maternal and fetal arterial blood samples 
(1 ml) were obtained simultaneously at -120, -60, 0, 5, 15, 30, 60, 120, 180 and 
240 min from the time of delivery of the amino acid solution and placed into vials 
containing 2 l of 0.3 M EDTA.  Blood samples were carefully inverted to allow 
mixing with the anticoagulant and immediately centrifuged at 10,000 X g for 1 
min.  Plasma was separated and stored at -80°C until assayed for amino acids. 
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Determination of amino acids 
Amino acids were determined using fluorometric HPLC methods involving 
precolumn derivatization with o-phthaldialdehyde as previously described (Wu et 
al., 1997).  High-performance liquid chromatography (HPLC)-grade water and 
methanol used for the analysis were obtained from Fisher Scientific (Fair Lawn, 
NJ, USA).  All other chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Plasma (40 µl) was deproteinated with 40 µl of 1.5 M HClO4, 
followed by addition of 20 µl of 2 M K2CO3 and 900 µl of HPLC water.  Amino 
acids in samples were quantified on the basis of authentic standards (Sigma-
Aldrich Corp., St. Louis, MO) using Millenium-32 Software (Waters, Milford, MA) 
(Wu & Meininger, 2008).  Concentrations of total amino acids at each time point 
were a mathematical sum of individual amino acids for the corresponding 
sampling. 
 
Calculations and statistical analyses 
Pharmacokinetics of the intravenous bolus of arginine or citrulline were 
analyzed after subtraction of baseline concentrations of plasma arginine and 
citrulline, using the single exponential model, plasma amino acid = a X e (-b X t), 
where “a” is maximum concentration in plasma and “b” is the elimination rate, as 
described previously (Wu et al., 2007a).  The internal exposure to exogenous 
arginine or citrulline was estimated by calculating the area under the 
concentration-time curve (AUC; a/b), with total clearance (CL) = amino acid 
dose/AUC.  The maximum concentration of arginine or citrulline (Cmax) in plasma 
was calculated by back-extrapolation of the elimination curve to time zero.  The 
biological half-life (T1/2) of the infused amino acid was determined from the 
elimination curve (Wu et al., 2007a).  
Differences in pharmacokinetic parameters between arginine and 
citrulline following administration to ewes were determined by one-way ANOVA. 
Data on concentrations of amino acids in plasma among  different time points 
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after arginine or citrulline infusion were analyzed by ANOVA for repeated 
measures, using the mixed model procedure of SAS (version 9.1, SAS Institute, 
Cary, NC, USA).  In addition, the linear regression procedure was used to 
compare slopes of amino acids throughout the sampling periods.  A P value of 
equal or less than 0.05 was designated as an indication of a statistical effect of 
treatment. 
 
Results 
Concentrations of amino acids in maternal or fetal plasma obtained at -
120, -60 and 0 min did not differ on either sampling day (P > 0.05).  Hence, 
averaged values for the -120, -60 and 0 min time points were used to represent 
baseline values as time 0 min.  In addition, baseline concentrations of all amino 
acids in maternal or fetal plasma were not different between sampling days (P > 
0.05), indicating a lack of carry-over effects of arginine administration on the 
subsequent day of sampling. 
 
Amino acids in maternal plasma 
A rapid increase in arginine and citrulline in maternal plasma was 
observed within 30 min after intravenous bolus administration of the two amino 
acids to ewes (Fig 2.1).  The concentration of arginine in maternal plasma 
peaked at 5 min after arginine infusion, with circulating levels remaining above 
(P < 0.01) the baseline for up to 120 min post-injection (Table 2.2, P < 0.01).  
Similar results were obtained for concentrations of citrulline after citrulline 
administration, except that the value at 240 min continued to be greater (Table 
2.3, P < 0.01) than the baseline level.   
Administration of arginine to the ewes did not (P > 0.10) increase 
concentrations of citrulline in maternal plasma at any time point post-injection 
(Fig. 2.1).  However, concentrations of arginine in maternal plasma increased (P 
< 0.05) between 5 and 240 min after citrulline infusion (Fig. 2.1).  Compared with 
the baseline, concentrations of ornithine in maternal plasma increased (P < 
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0.01) 94% between 15 and 30 min after exogenous arginine infusion and 
remained elevated (P < 0.05) up to 120 min post-injection (Table 2.2 and Fig. 
2.2).  In contrast, there were no changes (P > 0.10) in concentrations of 
ornithine in maternal plasma at any time point after citrulline administration 
(Table 2.3 and Fig. 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100
250
400
550
700
0 30 60 90 120 150 180 210 240
Ar
gi
n
in
e 
(nm
o
l/m
l)
Arginine infusion Citrulline infusion
100
250
400
550
700
0 30 60 90 120 150 180 210 240
Time after infusion (min)
Ci
tr
u
lli
n
e 
(nm
o
l/m
l)
*
+
+ +
+
+
+
+
+
+
+
*
+
*
+
*
+ *
+Ar
gi
n
in
e 
(nm
o
l/m
l)
Ci
tr
u
lli
n
e 
(nm
o
l/m
l)
Fig 2.1. Concentrations of arginine and citrulline in maternal plasma after 
a single intravenous bolus injection of 155 µmol/kg body weight of either 
arginine-HCl or citrulline on Day 135 ± 1 of gestation (∗,+ P < 0.05 for 
arginine and citrulline infusion, respectively). 
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Table 2.2.  Concentrations of arginine, citrulline and ornithine in maternal and fetal plasma after a single intravenous bolus  
injection of arginine-HCl (155 µmol L-arginine/kg body weight) to late pregnant ewes 
Time after bolus injection (min)   
0 5 15 30 60 120 180 240 SEM P value Amino acid 
mol/L   
 
Maternal plasma:       
  
 
Arginine  159d  668a   441b    377b 281c  234ce  181de  174de  55 <0.0001 
Citrulline  119  140   136    157 144  145  128  127  11 0.086 
Ornithine   56d    88bc     96ab    108a   93bc    82c    64d    58d    10 <0.0001 
 
Fetal plasma:       
  
 
Arginine  125c  128c   161b    190a 141bc  135c  128c  134c  12 <0.0001 
Citrulline  119  114   119    118 114  115  115  126    6 0.335 
Ornithine    35c    39bc     46ab      49a   47ab    41bc    38c    40bc    4 0.007 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for  
repeated measures and the Student-Newman-Keuls multiple comparisons test. 
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Fig 2.2. Concentrations of ornithine and lysine in maternal plasma after a single 
intravenous bolus injection of 155 µmol/kg body weight of either arginine-HCl or 
citrulline on day 135 ± 1 of gestation (∗,+  P < 0.05 for arginine and citrulline 
infusion, respectively). 
* 
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When compared with time 0, concentrations of aspartate, glutamate, 
asparagine, threonine, and leucine in maternal plasma decreased (P < 0.05) and 
concentrations of glutamine, taurine, methionine and lysine increased (P < 0.05) 
at various time points after bolus intravenous administration of arginine to ewes 
(Table 2.4).  Particularly, the concentration of aspartate in plasma decreased (P 
< 0.01) by 50% at 180 min, whereas the concentration of lysine increased (P < 
0.01) by 41% at 5 min (Fig 2.2).  In addition, concentrations of proline in 
maternal plasma were higher than the baseline between 5 and 180 min after 
arginine injection (Table 2.4).  Concentrations of other amino acids were not 
affected (P > 0.10) by the arginine treatment.   
Concentrations of aspartate in maternal plasma decreased (P < 0.01) 
between 30 and 240 min, while concentrations of proline increased between 30 
and 120 min after citrulline infusion.  However, concentrations of other amino 
acids did not change (P > 0.10) at any time point after citrulline injection to ewes 
(Table 2.5). 
 
Amino acids in fetal plasma 
Compared with baseline values, concentrations of arginine in fetal plasma 
were 50% and 29% greater (P < 0.01) at 30 min and 60 min after intravenous 
administration of arginine and citrulline to ewes, respectively (Fig. 2.3).  
Circulating levels of arginine in the fetus remained higher (P < 0.05) than 
baseline values between 30 and 240 min after citrulline administration, but only  
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Table 2.3.  Concentrations of arginine, citrulline and ornithine in maternal and fetal plasma after a single intravenous bolus 
injection of citrulline (155 µmol/kg body weight) to late pregnant ewes 
 
Time after bolus injection (min) 
  
Amino acid 0 5 15 30 60 120 180 240 SEM P value 
 mol/L   
 
Maternal plasma       
  
 
Arginine  156b  187a   202a   195a  192a  194a  198a  196a  28 0.014 
Citrulline  143f  765a   610b   459c  362d  306de  285e  256e  43 <0.0001 
Ornithine    59    61     67     65    66    69    69    67    7  0.134 
 
Fetal plasma       
  
 
Arginine  131c  134bc   138bc   148b  169a  166a  172a  164a    9 <0.0001 
Citrulline  112d  121d   131c   145b  162a  168a  170a  167a    5 <0.0001 
Ornithine    35bc    33c     36bc     44ab    49a    47a    53a    52a    8   0.0007 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for  
repeated measures and the Student-Newman-Keuls multiple comparisons test. 
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Table 2.4.   Concentrations of amino acids in maternal plasma after a single intravenous bolus injection of arginine-HCl  
(155 µmol L-arginine/kg body weight) to late pregnant ewes 
Time after bolus injection (min)  
0 5 15 30 60 120 180 240 SEM Amino acid 
mol/L  
P value 
Aspartate 12a 10ab 8.4bc 9.9ab 7.6bc 8.1bc 6.0c 7.3bc 1.8 0.006 
Glutamate 73ab 69ab 70ab 78a 69ab 78a 64b 62b 11 0.047 
Asparagine 22a 23a 22a 24a 22a 22a 17b 18b 3 0.005 
Serine 82 78 71 80 65 69 59 66 14 0.081 
Glutamine 179b 205ab 206ab 224a 203ab 209ab 179b 184b 38 0.023 
Histidine 31ab 38a 35a 35a 33ab 33ab 29b 29b 4 0.040 
Glycine 346 406 381 414 385 415 381 364 55 0.398 
Threonine 67ab 70a 68a 75a 66ab 69a 57c 58bc 10 0.008 
-Alanine 22 22 22 24 22 24 21 22 6 0.432 
Taurine 62bc 79a 74ab 76ab 64bc 67abc 52c 56cd 9 0.002 
Alanine 112b 117ab 113b 126a 112b 118ab 99c 98c 15   0.0009 
Tyrosine 43 47 45 50 45 47 40 42 6 0.087 
Tryptophan 31 31 29 32 29 31 27 29 5 0.627 
Methionine 18bc 21a 20abc 23a 21ab 21ab 18c 19bc 4 0.020 
Valine 92 83 63 89 81 84 70 72 13 0.251 
Phenylalanine 42 52 54 59 51 54 47 51 18 0.188 
Isoleucine 48 49 48 54 47 50 42 44 5 0.117 
Leucine 89ab 92ab 89ab 97a 87abc 89ab 75c 81bc 11 0.055 
Lysine 69d 97a 91a 95a 81b 77bc 63d 69cd 10 <0.0001 
Cysteine 165 167 165 166 165 165 166 166 9 0.995 
Proline 96e 109d 118c 130b 147a 126bc 109d 99e 4 <0.0001 
Total AA 1701bc 1864ba 1792bc 1960a 1804abd 1856ab 1620cd 1634cd 169 0.020 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for 
repeated measures and the Student-Newman-Keuls multiple comparisons test.  AA, amino acids. 
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Table 2.5.  Concentrations of amino acids in maternal plasma after a single intravenous bolus injection of citrulline  
(155 µmol/kg body weight) to late pregnant ewes 
 
Time after bolus injection (min) 
  
Amino acid 0 5 15 30 60 120 180 240 SEM P value 
 mol/L   
Aspartate     9.6a     8.6abc     8.8
ab
     7.6bc     7.6bc     7.4bc     7.0c     7.3bc    1 0.040 
Glutamate    69    72    76    69    70    68    71    69    8 0.750 
Asparagine    24    25    31    24    24    22    23    23    3 0.258 
Serine    70    66    68    64    63    64    64    64   10 0.543 
Glutamine   203   234   244   228   222   220   223   224   39 0.432 
Histidine    35    41    42    38    36    35    37    36    5 0.250 
Glycine   326   380   399   375   358   369   374   385   52 0.309 
Threonine    69    71    75    70    69    67    72    73    10 0.940 
-Alanine    21    22    22    21    21    21    21    21    5 0.384 
Taurine    69    79    83    78    80    71    65    67    8 0.286 
Alanine   106   113   117   107   106    99   102    99   15 0.226 
Tyrosine    44    53    55    52    53    50    53    53    6 0.232 
Tryptophan    31    35    36    34    33    33    35    34    5 0.176 
Methionine    19    20    20    19    19    18    19    19    2 0.885 
Valine    100   117   120   110   112   105   112   112   13 0.431 
Phenylalanine    45    42    43    40    40    38    40    40    7 0.937 
Isoleucine    53    60    64    54    43    53    54    54    6 0.344 
Leucine    93   102   104    95    94    88    91    93   11 0.554 
Lysine    78    88    93    88    88    87    90    90   10 0.633 
Cysteine  168  165  164 164 172 167  166  162    9 0.193 
Proline    93d    93d    96cd  110b 121a 100c    97cd    93d    4 <0.0001 
Total AA 1725 1886 1959 1848 1833 1782 1806 1818 149 0.590 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for repeated  
measures and the Student-Newman-Keuls multiple comparisons test.  AA, amino acids. 
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between 15 and 30 min after arginine administration (Fig. 2.3 and Tables 2.2 
and 2.3).  In contrast, concentrations of citrulline in fetal plasma increased (P < 
0.01) between 15 and 240 min after intravenous infusion of citrulline to ewes, but 
were not altered (P > 0.10) at any time point after administration of arginine (Fig. 
2.3 and Tables 2.2 and 2.3). 
 Concentrations of ornithine in fetal plasma increased (P < 0.01) between 
15 and 30 min after bolus intravenous administration of arginine to ewes, but did 
not change (P > 0.10) at other time points post-injection, when compared with 
the baseline value (Fig. 2.4).  Interestingly, in response to citrulline infusion, 
concentrations of ornithine in fetal plasma increased substantially (P < 0.05) at 
30 min and remained elevated throughout the sampling period for up to 240 min 
(P < 0.05). 
Arginine infusion decreased (P < 0.05) concentrations of leucine in fetal 
plasma between 15 and 120 min, and increased concentrations of proline 
between 15 and 180 min post-administration, but had no effect on other amino 
acids (Table 2.6).  In contrast, citrulline administration increased (P < 0.05) 
concentrations of lysine in fetal plasma between 120 and 240 min and 
concentrations of proline between 15 and 240 min, but did not affect (P > 0.10) 
other amino acids at any time point (Table 2.7). 
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Fig 2.3. Concentrations of arginine and citrulline in fetal plasma after a single 
intravenous bolus injection of 155 µmol/kg body weight of either arginine-HCl or 
citrulline to ewes on Day 135 ± 1 of gestation (∗,+ P < 0.05 for arginine and 
citrulline infusion, respectively).  
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Fig 2.4. Concentrations of ornithine and lysine in fetal plasma after a single 
intravenous bolus injection of 155 µmol/kg body weight of either arginine-HCl 
or citrulline to ewes on Day 135 ± 1 of gestation (∗,+ P < 0.05 for arginine 
and citrulline infusion, respectively). 
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Table 2. 6. Concentrations of amino acids in fetal plasma after a single intravenous bolus injection of arginine-HCl  
(155 µmol /kg body weight) to late pregnant ewes 
 Time after bolus injection (min) 
  
Amino acid 0 5 15 30 60 120 180 240 SEM P value 
 mol/L   
Asp      4.7      5.0      5.8      5.8      4.2      4.6     3.6      4.3    0.7 0.169 
Glu    34    29    32    32    29    28    28    31    3 0.418 
Asn    24    22    19    20    21    21    22    23    2 0.267 
Ser   292   336   260   270   277   292   303   309   58 0.536 
Gln   210   191   188   183   188   180   217   189   17 0.683 
His    30    26    25    26    23    26    29    32    3 0.082 
Gly   278   267   300   288   260   270   289   317   29 0.082 
Thr   145   155   124   154   128   134   133   139   25 0.703 
-Ala   151   152   138   142   143   148   147   155   46 0.523 
Tau    94   103    79    86    90    89    89   103   17 0.508 
Ala   154   142   132   137   140   144   146   153   19 0.202 
Tyr    61    59    55    57    55    55    56    59   12 0.689 
Trp    76    68    62    62    71    70    71    73   28 0.786 
Met    24    23    21    21    22    23    23    24    3 0.316 
Val   108   103    94    98   101   103   102   130   21 0.262 
Phe    73    67    67    68    67    68    68    57   23 0.891 
Ile    32    30    29    29    30    32    28    33    5 0.583 
Leu    70a    63ab    61b    61b    62b    61b    63ab    71a    8 0.040 
Lys    30    24    24    25    26    29    28    30    5 0.326 
Cys  176  171  173  174  175  174  171  176    9 0.748 
Pro    97d    99de  106c  110bc  122a  115b  105ce    99de    5 <0.0001 
Total AA 2108 2134 1990 2028 2048 2030 2121 2135 170 0.434 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for  
repeated measures and the Student-Newman-Keuls multiple comparisons test. AA, amino acids. 
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Table 2.7.  Concentrations of amino acids in fetal plasma after a single intravenous bolus injection of citrulline  
(155 µmol/kg body weight) to late pregnant ewes 
 
Time after bolus injection (min)  
 
Amino acid 0 5 15 30 60 120 180 240 SEM P value 
 mol/L   
Asp      3.8      4.6      4.4      3.7      3.4      3.6      3.9      3.8    0.4 0.325 
Glu    25    24    23    25    23    23    24    26    2 0.756 
Asn    22    21    20    22    21    21    23    23    3 0.801 
Ser   260   254   243   266   261   249   270   273   42 0.320 
Gln   182   170   169   175   163   157   168   173   16 0.283 
His    26    26    24    25    25    24    26    29    2 0.367 
Gly   231   242   228   239   233   220   233   250   28 0.475 
Thr   116   106   100   117   109   106   118   116    9 0.302 
-Ala    92    85    87    96    84    84    91    96   15 0.356 
Tau   113   108   110   112   112   111   118   119   28 0.615 
Ala   135   129   125   145   138   134   149   159   21 0.216 
Tyr    56    52    50    57    56    54    59    63   12 0.291 
Trp   132   129   123   146   147   131   145   122   64 0.938 
Met    17    16    16    16    17    16    18    18    1 0.309 
Val   121   109   107   115   110   107   118   112    8 0.653 
Phe    46    44    43    46    47    44    49    50    4 0.295 
Ile    33    29    29    29    31    31    34    30    3 0.699 
Leu    61    56    58    61    59    57    63    62    4 0.601 
Lys    31cd    29cd    28d    33abc    31bc    33abc    35ab    37a    5 0.021 
Cys  179  176  174  169 175  175  173  170   10 0.280 
Pro  103d  108cd  110c  119b 128a  123ab  121b  120b   10 <0.0001 
Total AA 1984 1981 1970 2027 1973 1983 2039 2050 167 0.510 
Data are means with pooled SEM, n = 6.  Values sharing different superscripts within a row differ, as analyzed by one-way ANOVA for  
repeated measures and the Student-Newman-Keuls multiple comparisons test.  AA, amino acids. 
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Pharmacokinetics of arginine and citrulline in ewes 
 The AUC values were greater (P < 0.05) in maternal plasma after bolus 
intravenous administration of citrulline compared to arginine (Table 2.8).  
Accordingly, CL values were lower (P < 0.05) and the T1/2 greater after citrulline 
injection.  Maximum concentrations (Cmax) of arginine and citrulline in maternal 
plasma did not differ (P > 0.10) after their intravenous infusion into ewes (Table 
2.8). 
 
 
 
Table 2.8. Pharmacokinetics of arginine and citrulline in late pregnant ewes receiving a single 
intravenous bolus injection of L-arginine or L-citrulline (155 mol/kg body weight) 
Amino acid administered Parameters 
Arginine Citrulline P value 
AUC, (µmol • min)/mL 29.0 ± 6.3 70.8 ± 13.3 0.017 
CL, mL/(min • kg) 6.60 ± 1.41 2.64 ± 0.6 0.031 
T1/2 , min 45.3 ± 7.0 89.2 ± 11.6 0.009 
Cmax, µmol/L 453.4 ± 78.1 530.9 ± 40.1 0.398 
Data are means  ± SEM, n=6, and analyzed by paired t-tests.  
AUC, area under the concentration-time curve; CL, total clearance; T1/2, biological half life of amino acid; Cmax, maximal 
concentration. 
 
 
 
Discussion 
 Arginine is a nutritionally essential amino acid for optimal growth and 
development of the fetus (Wu et al., 2004a) due to underdevelopment of the 
intestinal-renal axis for endogenous arginine synthesis from glutamine/glutamate 
and proline (Wu et al., 2004b).  The fetus obtains arginine directly from maternal 
circulation via utero-placental blood flow, as well as indirectly from citrulline via 
reactions catalyzed by argininosuccinate synthase and argininosuccinate lyase 
(Wu et al., 2008).  Because citrulline is a neutral amino acid and its 
administration does not disturb acid-base balance (Wu & Meininger, 2000), there 
is increasing interest in the use of citrulline as a precursor for arginine in non-
pregnant animals and humans (Morris, 2006; Wu et al., 2007b; Moinard et al., 
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2008); however, there have been no reports of studies to determine the efficacy 
of exogenous citrulline for arginine synthesis in the mother or fetus.  The major 
finding of the present study is that intravenous administration of citrulline was 
more effective than that of arginine to sustain a prolonged increase in 
concentrations of arginine in fetal circulation (Tables 2.2 and 2.3).  Consistent 
with this observation, the biological half-life of citrulline in maternal plasma of 
ewes was twice that of arginine (Table 2.8).  These results can be explained by 
higher activities for arginase than for argininosuccinate synthase and 
argininosuccinate lyase (the enzymes that are responsible for citrulline 
catabolism) in extrahepatic tissues of adult mammals (Wu & Morris, 1998).  To 
our knowledge, this is the first report on citrulline metabolism in pregnant 
mammals. 
There is a high rate of arginine turnover in pregnant ewes, due to its rapid 
clearance from maternal plasma (Wu et al., 2007a).  To confirm and extend this 
observation, we found that concentrations of arginine and ornithine, a product of 
arginine metabolism, in plasma of ewes on Day 135 ± 1 of gestation rose to 
peak values within 5 min after a bolus intravenous administration of arginine and 
declined rapidly thereafter to baseline values (Table 2.2).  Because NO 
production is quantitatively a minor pathway of arginine catabolism in healthy 
mammals (Wu & Morris, 1998), arginine administration had no effect on 
concentrations of citrulline (a co-product of NO synthase) in maternal plasma 
(Table 2.2).  In contrast, intravenous infusion of citrulline into ewes markedly 
increased concentrations of both citrulline and arginine, but not ornithine, in 
maternal plasma (Table 2.3).  Notably, concentrations of citrulline and arginine in 
maternal plasma remained elevated throughout a 4 h period after administration 
of a single bolus of citrulline into the maternal venous circulation.  Furthermore, 
even at 4 h, the concentrations of citrulline and arginine in the fetus were 49% 
and 25% greater, respectively, than the baseline values (Table 2.3). 
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Results of the present study suggest that citrulline is readily converted 
into arginine in maternal tissues.  In support of this view, aspartate (a substrate 
of argininosuccinate synthase in the pathway of arginine synthesis from 
citrulline) was the only amino acid whose concentrations in maternal plasma 
were reduced due to its extensive utilization for arginine formation in response to 
citrulline administration (Table 2.5).  The findings of the present study also 
suggest that the citrulline-derived arginine is not substantially degraded to 
generate ornithine via arginase in pregnant ewes.  This further substantiates 
evidence that there is complex metabolism of arginine via its compartmentalized 
pathways in animals (Wu & Morris, 1998).  Whether intravenous administration 
of arginine or citrulline into pregnant ewes is capable of increasing arginine 
availability in the fetus must be determined experimentally. 
A substantial rise in concentrations of amino acids (including arginine) in 
maternal blood can result in an increase in uptake into the fetal circulation 
(Battaglia, 2002; Thureen et al., 2002; Wilkes et al., 2003).  However, the rate of 
delivery of an amino acid from the uterus to the fetus depends not only on its 
transport from maternal circulation to the placenta but also on its utilization and 
metabolism by placental cells and subsequent efflux from the placenta into the 
fetus (Battaglia & Regnault, 2001; Wu et al., 2004a).  These critical events 
involve placental transport systems at both maternal and fetal surfaces of the 
placenta (Battaglia & Regnault, 2001).  In sheep,  the y+ and y+L cationic amino 
acid transport systems on both surfaces of the placenta are responsible for net 
transport  of arginine to the fetus (Wu & Morris, 1998; Regnault et al., 2005a).  A 
high activity of arginase in ovine placentomes rapidly hydrolyzes arginine into 
urea and ornithine (Kwon et al., 2003b).  Thus, although peak concentrations of 
arginine in maternal plasma within 5 min of its intravenous administration to 
ewes was 320% greater than baseline values (Table 2.2), concentrations of 
arginine in fetal plasma increased only 52% at 30 min and returned to the 
baseline values at 60 min (Table 2.5).  In contrast, intravenous administration of 
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citrulline to ewes resulted in progressive increases in concentrations of both 
citrulline and arginine in fetal plasma between 5 and 60 min and, importantly, 
these elevated levels were sustained throughout the remainder of the sampling 
period.  Indeed, concentrations of citrulline, arginine, ornithine and proline in 
fetal plasma at 4 h were 49%, 25%, 48% and 17% greater than baseline values, 
respectively.  Collectively, these results indicate for the first time, the prolonged 
effects of intravenous citrulline administration into ewes in enhancing arginine 
availability in the fetus. 
Changes in concentrations of amino acids other than arginine, citrulline, 
ornithine and aspartate in maternal and fetal plasma after intravenous 
administration of arginine or citrulline deserve comments.  Basic amino acids 
share the same transport systems in plasma membranes (Christensen, 1990).  
Moreover, the systems bo,+, Bo,+, and y+L can transport both basic and large 
neutral amino acids into cells (Palacin et al., 1998).  Thus, with a rise in 
concentrations of arginine in plasma of ewes, uptakes of lysine (a basic amino 
acid) as well as proline and methionine (large neutral amino acids) by maternal 
tissues would be reduced, leading to transient increases in concentrations of 
these amino acids in the maternal circulation (Table 2.5).  An increase in 
concentrations of glutamine in maternal plasma after arginine infusion is likely 
due to the formation of glutamine via the pathway involving arginase, ornithine 
aminotransferase, and glutamine synthetase (Wu & Morris, 1998).  Interestingly, 
intravenous administration of arginine or citrulline increased concentrations of 
proline in fetal plasma, but had no significant or prolonged effects on 
concentrations of other neutral amino acids (Tables 2.6 and 2.7).  This finding is 
exciting, because proline has been recently suggested to have an important role 
in conceptus metabolism and development (Wu et al., 2008). Also, it indicates 
that the dosages of arginine or citrulline administered to pregnant ewes do not 
compromise the availability of all amino acids in the fetus, therefore, remaining 
accessible to promote fetal growth. 
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 In summary, results of this pharmacokinetic study revealed that the 
biological half-life of citrulline in plasma of pregnant ewes is approximately twice 
that for arginine. Therefore, intravenous administration of citrulline into ewes is 
more effective than arginine in maintaining prolonged increases in available 
arginine in both maternal and fetal circulations, without reducing concentrations 
of all amino acids in the fetus.  These novel findings should aid in the design of 
an effective arginine or citrulline therapeutic solution to ameliorate intrauterine 
growth restriction, a significant problem in both human medicine and animal 
production (Wallace et al., 2005; Wu et al., 2006).  
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CHAPTER III 
PARENTERAL ADMINISTRATION OF ARGININE PREVENTS FETAL 
GROWTH RESTRICTION IN UNDERNOURISHED EWES 
 
Introduction 
 Intrauterine growth restriction (IUGR) is a major health problem 
worldwide, representing 11% of all newborns in developing countries and a large 
number of all newborns in developed nations, e.g. 2-5% in the U.S. (Murphy et 
al., 2006).  Maternal undernutrition, which occurs under conditions such as 
inadequate supply of food or severe nausea and vomiting in pregnant women, is 
an important factor that adversely impacts fetal growth (Attard et al., 2002; Wu et 
al., 2004a).  Intrauterine growth restriction results in emotional stress and 
contributes to extremely high costs of health care due to perinatal and life-long 
medical complications (Mari & Hanif, 2007).  For example, ~50% of non-
malformed stillbirths result from IUGR and 5% of premature deliveries are due to 
poor growth of fetuses in utero (Bryan & Hindmarsh, 2006; Pallotto & Kilbride, 
2006).  Also, infants who weigh < 2.5 kg at birth have 5- to 30-times higher rates 
of perinatal mortality than newborns who have average birth weights, and these 
rates are 70- to 100-times higher for infants weighing < 1.5 kg at birth (Pallotto & 
Kilbride, 2006).  Furthermore, surviving infants with IUGR are at increased risk 
for neurological, respiratory, intestinal, and circulatory disorders (Gluckman & 
Hanson, 2006).  To date, there is no therapeutic means for preventing or 
ameliorating IUGR, the current management being empirical and primarily aimed 
at selecting a safe time for delivery (Resnik, 2002; Mari & Hanif, 2007). 
 Arginine, a nutritionally essential amino acid for the fetus (Wu et al., 
2004b), is a precursor  for synthesis of nitric oxide (NO) and polyamines in cells 
(Wu & Morris, 1998).  Nitric oxide is a major endothelium-derived vasodilator, 
whereas polyamines are key regulators of DNA and protein synthesis (Wu and 
Morris, 1998).  Consequently, arginine may play a critical role in placental 
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growth (including vascular growth), utero-placental blood flow, and hence the 
transfer of nutrients from mother to fetus (Wu et al., 2006).  We found that 
maternal undernutrition reduced arginine concentrations in maternal and fetal 
plasma of ewes (Kwon et al., 2004a) and decreased the availability of arginine, 
polyamines and NO synthesis in the conceptus (fetus and associated 
membranes) (Wu et al., 1998a; Wu et al., 1998b; Kwon et al., 2004a). 
Interestingly, direct infusion of arginine into the fetal femoral vein for 3 to 4 h 
increased fetal whole-body protein accretion in an ovine model of IUGR induced 
by placental insufficiency (De Boo et al., 2005). 
 We hypothesized that parenteral administration of arginine to underfed 
ewes would ameliorate or prevent fetal growth retardation.  This hypothesis was 
tested using an ovine model of IUGR, which is an established and valuable 
animal experimental approach for studying fetal growth in humans (Schroder, 
2003; Luther et al., 2005). 
 
Materials and methods 
Ewes  
Fifteen multiparous Suffolk crossbred ewes weighing 76.7 ± 2.8 kg (mean 
± SEM) were mated to a single fertile Suffolk ram when detected in estrus (Day 
0) and 12 h later, to minimize paternal genetic effects on size and weight of the 
fetuses.  At Day 21 post-mating, ewes were transported to the Texas A&M 
Animal Science Teaching, Research and Extension Center (ASTREC), where 
they were individually housed in outdoor covered pens with free access to 
drinking water and allowed a 7-day period of acclimation.  Transabdominal 
ultrasonography (7.5 MHz probe, Aloka Inc. console) was used to confirm 
pregnancy.  Ewes were fed a wheat, cottonseed, rice mill and alfalfa-based diet 
(Table 3.1; Producers Cooperative Association, Bryan, TX, USA) to meet 100% 
of the NRC (National Research Council, 1985) nutrient requirements for 
pregnant sheep. Ewes were fed once daily between 0700 h and 0800 h. This 
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study was approved by the Texas A&M University Institutional Animal Care and 
Use Committee. 
 
 
 
Table 3.1. Exp. 2/ Composition of the diet (as-fed basis)1 
 
 
Ingredients  
Content 
Wheat midds  42.25% 
Cottonseed hulls  27.4% 
Rice mill feed  15% 
Dehydrated alfalfa  10% 
Liquid binder  2.5% 
Ground limestone  1.76% 
Sodium bicarbonate  0.50% 
Mineral mixture  0.50% 
Vitamin mixture  0.09% 
 
1Provided the following in the diet: 10.2% crude protein; 0.60% arginine; 3.4% crude fat; 22.3% 
crude fiber; 1.0% calcium; 0.50% phosphorus; 1.01% salt; 0.94% potassium; 0.18% sulfur; 
0.25% magnesium; 226 ppm manganese; 228 ppm iron; 11.3 ppm copper; 0.35 ppm cobalt; 146 
ppm zinc; 1.00 ppm iodine; 0.53 ppm selenium; 1.00 ppm molybdenum; 8,110 IU/kg vitamin A; 
13.2 IU/kg vitamin E; and 455 IU/kg vitamin D. 
 
 
 
Experimental design 
At Day 28 of pregnancy, ewes were assigned randomly to be fed either 100% 
(n=5) or 50% (n=10) of the daily NRC nutrient requirements for pregnant sheep 
(NRC, 1985). The diet and daily feeding schedule were the same as provided 
during the acclimation period. Ewes were weighed weekly, before feeding, and 
diets were adjusted on an individual basis according to recorded live-weight 
changes. The 50% level of underfeeding was adopted because it has been 
shown to reduce placental and fetal growth in sheep (Vonnahme et al., 2003; 
Kwon et al., 2004a; Satterfield et al., 2007).   
One to three days before Day 60 of gestation, a 16 G X 13 cm 
polyurethane peripheral catheter (Milicath, MILA international, Inc., Florence, 
KY, USAwas placed into the jugular vein of the ewes and fixed with suture 
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points to the skin of the neck. Prior to its insertion, wool at the catheterization 
site was clipped (number 40 blade, Oster, McMinville, TN, USA), and the skin 
was scrubbed with an iodine-soap solution (Povidine-iodine, Vedadine Surgical 
Scrub, VEDCO St Joseph, MO, USA) and wiped with 70% ethanol. Once fixed, 
the catheter was fitted with a 30.5 cm microbore extension (Hospira Inc., Lake 
Forest, IL) which was screwed, by means of a hub, onto the catheter at one end, 
sutured to the skin at the joint site with the catheter, then at half-length on the 
back of the neck, and again at the far end close to the base of the head adjacent 
to the occipital region, thus allowing access from the back of the ewe. The 
extension was capped with an intermittent infusion plug (Kendall Argyle, Tyco 
Healthcare Retail Group, Inc., King of Prussia, PA, USA) that permitted repeated 
insertion of regular disposable needles. After the catheter and extension were 
positioned and fixed, a covering elastic cotton stocking was placed around the 
neck of the ewe, in an effort to maintain a clean and protected area. Initially, 
Vetrap bandaging tape was used (3M Animal Care Products, St. Paul, MN, 
USA) for this purpose, but it quickly contracted due to continuous movement of 
the neck; therefore, an elastic cotton was chosen to replace the tape to avoid 
development of edema or other associated problems. The intermittent infusion 
plugs that capped the catheter extensions were periodically changed throughout 
the experimental period.  Extensions and catheters were only replaced when 
damaged or pulled out. During this study, 10 ml disposable syringes (latex-free, 
luer-lok tip, Becton Dickinson, Franklin Lakes, NJ, USA) and 21 G X 3.8 cm 
needles (Precision glide, Becton Dickinson, Franklin Lakes, NJ, USA)  were 
used for delivery of solutions. 
Between Day 60 of pregnancy and parturition, control-fed ewes (Group 
100% NRC; n = 5) received 10 ml of sterile saline solution as a bolus injection 
(sodium chloride 0.9%, Hospira Inc. Lake Forest, IL) through the jugular catheter 
three times daily, and underfed ewes were randomly divided in two groups, to 
receive either 10 ml of sterile saline solution (Group 50% NRC; n = 5) or sterile 
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L-arginine-HCl solution (155 mol arginine/kg body weight; Sigma-Aldrich Co. St 
Louis MO, USA) (Group 50% + Arginine; n = 5) three times daily (0800, 1500, 
and 2200 h). The arginine-HCl solution was prepared twice per week, using 
sterile physiological saline (sodium chloride 0.9%, Hospira Inc., Lake Forest, IL, 
USA) with a final concentration of 1.5 g arginine per 5 ml. The pH was adjusted 
to 7.0 with 1 M NaOH and the solution filtered through a 0.22 m cellulose 
acetate filter (Corning Inc, NY, USA) into re-usable sterile glass containers fitted 
with adjustable-sealing sterile rubber caps. The prepared L-arginine-HCl solution 
was kept at -20°C and thawed at 4°C the night before being used. Disposable 
10 ml syringes (latex free, luer-lok tip, Becton Dickinson, Franklin Lakes, NJ, 
USA) were marked with ewe identification numbers and filled up in the 
laboratory with either saline or arginine-HCl in saline solution before every 
infusion. The arginine-HCl saline solution was used throughout the day, with the 
rubber cap on the bottle being cleaned with 70% ethanol before insertion of the 
disposable needle. A bacteriological culture of randomly selected saline and 
arginine solutions was performed by the Texas Medical Diagnostic Laboratory 
(College Station, TX) on two occasions to verify sterility. Between infusions, 
catheters were flushed and filled with 0.75 ml heparin solution (40 units/ml, 
American Pharmaceutical Partners, Inc., Schaumburg, IL) to prevent clotting and 
maintain patency. 
Every 10 days from Day 60 of pregnancy until parturition, approximately 7 
ml of maternal blood were obtained from all ewes from the contralateral jugular 
vein to the catheterized jugular vein, using anticoagulant-free, sterile vacuum 
tubes (Vacutainer, Becton Dickinson, Franklin Lakes, NJ) and 20 G X 3.8 cm 
blood collection  needles (Vacutainer, Becton Dickinson, Franklin Lakes, NJ).  
Blood was drawn in the morning immediately before the first infusion of either 
saline or arginine-HCl saline solution.  Samples were placed on ice and 
immediately centrifuged at 3,000 x g for 15 min.  Serum was separated and 
stored at -80°C until analyzed for amino acids, metabolites and hormones. 
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At parturition, a portable scale was used to record birth weights of lambs.  
Care was taken to weigh the newborns immediately after birth. 
 
Determination of amino acids, other metabolites and hormones in serum 
Deproteinated serum was used for the analyses for amino acids, 
ammonia, urea, glucose, lactate, glycerol, and -hydroxybutyrate (BHB), 
whereas whole serum was assayed for free fatty acids (FFA), triglycerides, 
insulin and growth hormone (GH).  Amino acids were determined by fluorometric 
HPLC methods involving precolumn derivatization with o-phthaldialdehyde as 
described (Wu et al., 1997).  -Hydroxybutyrate was measured enzymatically by 
a spectrophotometric method using 3-hydroxybutyrate dehydrogenase (Wu et 
al., 1991).  Free fatty acids were quantified by an enzymatic colorimetric method 
using the assay kit from Waco Chemicals Inc (Richmond, VA, USA).  Glucose 
was determined enzymatically using a spectrophotometric method involving 
hexokinase and glucose-6-phosphate dehydrogenase (Fu et al., 2005).  Glycerol 
and L-lactate were quantified using enzymatic fluorometric methods as 
described by Fu et al. (2005) and Wu et al. (1991), respectively.  Triglycerides 
were determined enzymatically using the InfinityTM assay kit from Thermo 
Electron Corporation (Pittsburgh, PA, USA).  Ammonia and urea were 
determined using fluorometric methods involving glutamate dehydrogenase and 
urease (Wu, 1995; Wu et al., 1995).  Insulin was analyzed using the ovine 
insulin ELISA microplate kit from Mercodia AB (Uppsala, Sweden), whereas 
growth hormone was quantified by RIA (Powell & Keisler, 1995; Lalman et al., 
2000) validated for ovine serum. 
 
Statistical analyses 
Data on lamb birth weight were statistically analyzed by one-way ANOVA, 
using a variance-covariance matrix that considered the effects of number of 
lambs born (singles or twins) (Steel et al., 1997).  Data on concentrations of 
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amino acids, other metabolites, and hormones in serum were analyzed by two-
way ANOVA for repeated measures to determine the effects of day of 
pregnancy, treatment, and day of pregnancy x treatment interactions (Steel et 
al., 1997).  Where there was a statistically significant day x treatment interaction, 
effects of day within nutritional treatment were analyzed by one-way ANOVA.  
Log transformation of variables was performed when variance of data was not 
homogenous among treatment groups, as assessed using the Levene’s test.  P 
values  0.05 were taken to indicate statistical significance.  
 
Results 
 
Body weights of ewes and newborn lambs 
Feed intake did not differ between saline- and arginine-infused underfed 
ewes throughout the experimental period. The underfed ewes consumed 50% 
less feed than the control-fed ewes (Table 3.2).  On the day of onset of nutrient 
restriction (Day 28), the live weight of the ewes did not differ between control-fed 
(100% NRC-requirement), underfed (50% NRC-requirement), and arginine-
treated underfed (50% NRC + Arg) groups (Table 3.3).  At the end of pregnancy, 
control-fed ewes gained 13% in body weight over that at Day 28, whereas the 
underfed ewes receiving either intravenous saline or arginine lost 6.7% and 
2.1% of their body weight, respectively (Table 3.3).  The length of gestation was 
142.3 ± 1.2 days (n=15) and did not differ among the three groups of ewes.  
There were singleton and twin lambs born to ewes in all groups.  Both the 
control-fed and the 50% NRC + Arg groups had three singleton and two twin 
lambs each, while the 50% NRC group had two singleton and three twin lambs.  
Birth weights for single lambs were greater (P < 0.01) than those for individual 
lambs born as twins (4.03 ± 0.21 vs 3.17 ± 0.14 kg, respectively).  Thus, fetal 
number per ewe was included in the statistical analysis as a covariate to assess 
differences in weight at birth between groups.  
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Table 3.2. Feed intake (g/kg body weight/day) over the experimental period in control-
fed (100%NRC) and underfed ewes (50%NRC) with or without intravenous arginine  
treatment 
 Feed intake 
Week of pregnancy 100% NRC 50% NRC 50% NRC + Arg 
  
5 22.5 ± 0.53 a 11.0 ± 0.22 b 11.1 ± 0.32 b 
6 22.6 ± 0.57 a 11.3 ± 0.26 b 11.4 ± 0.41 b 
7 22.6 ± 0.62 a 11.2 ± 0.31 b 11.4 ± 0.41 b 
8 22.6 ± 0.62 a 11.2 ± 0.24 b 11.3 ± 0.41 b 
9 22.6 ± 0.54 a 11.3 ± 0.36 b 11.4 ± 0.43 b 
10 22.7 ± 0.62 a 11.3 ± 0.07 b 11.3 ± 0.44 b 
11 22.3 ± 0.71 a 11.3 ± 0.33 b 11.3 ± 0.48 b 
12 22.2 ± 0.67 a 11.3 ± 0.33 b 11.3 ± 0.44 b 
13 22.3 ± 0.66 a 11.3 ± 0.32 b 11.3 ± 0.45 b 
14 21.9 ± 0.66 a 11.3 ± 0.17 b 11.2 ± 0.39 b 
15 22.0 ± 0.73 a 11.2 ± 0.13 b 11.1 ± 0.39 b 
16 22.0 ± 0.76 a 11.3 ± 0.29 b 11.3 ± 0.41b 
17 22.0 ± 0.68 a 11.4 ± 0.31 b 11.1 ± 0.33 b 
18 22.0 ± 0.70 a 11.5 ± 0.28 b 11.2 ± 0.37 b 
19 22.0 ± 0.66 a 11.3 ± 0.09 b 11.2 ± 0.42 b 
20 21.5 ± 0.37 a 11.7 ± 0.24 b 11.4 ± 0.43 b 
21 21.8 ± 0.35 a 11.2 ± 0.15 b 11.1 ± 0.41b 
 
Data are means±SEM, n = 5.  
a-b: Means sharing different superscripts within a row differ (P < 0.01). 
 
 
 
The birth weights of lambs from saline-infused undernourished ewes were 
23% lower (P < 0.01) than those for lambs born to control-fed dams (Table 3.3).  
Arginine infusion to underfed ewes increased (P < 0.01) birth weight of lambs by 
21%, when compared with underfed ewes receiving saline infusion (Table 3.3).  
There was no difference (P > 0.10) in birth weights between control-fed and 50% 
NRC + Arg groups. 
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Table 3.3.  Body weights of control and underfed ewes on Days 28 and 140 of pregnancy 
and weights of lambs at birth 
Body weight of ewes 
(kg)  
Day of pregnancy Weight change   
Group 
Day 28 Day 140 (Day 140 - Day 28) 
 
Birth weight of 
Lambs 
(kg) 
Control-fed 71.1 ± 4.7 80.2 ± 4.7   9.1 ± 3.2a  3.99 ± 0.24a
Underfed 79.5 ± 2.7 74.2 ± 1.8 -8.4 ± 3.9b  3.06 ± 0.16b
Underfed + Arginine 80.3 ± 5.7 78.6 ± 6.3 -4.1 ± 1.6b  3.70 ± 0.21a
 
Data are means ± SEM, n = 5.  a-b: Means sharing different superscripts within a column differ (P < 0.01). 
 
 
 
Concentrations of amino acids in maternal serum 
 Concentrations of amino acids in serum of control-fed ewes and underfed 
ewes with or without arginine are summarized in Table 3.4.  Levels of glutamate, 
glutamine, glycine and -alanine in maternal serum were not affected by 
maternal underfeeding.  However, concentrations of all other amino acids were 
lower (P < 0.05) in saline-infused undernourished ewes, compared to control-fed 
ewes.  Concentrations of asparagine, histidine, threonine, citrulline, taurine, 
tyrosine, tryptophan, valine, phenylalanine and lysine were lower (P < 0.05) in 
the 50% NRC + Arg group than in control ewes, but did not differ from values for 
ewes in the 50% NRC group.  Concentrations of methionine, isoleucine, leucine, 
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ornithine, cysteine and proline in maternal serum were 19-55% greater in the 
50% NRC + Arg group (P < 0.01) than in the 50% NRC ewes, and 15-40% lower 
(P < 0.01) than for the control-fed ewes.  Notably, concentrations of arginine in 
maternal serum increased (P < 0.01) by 69% in the 50% NRC + Arg ewes 
compared with the 50% NRC ewes and were similar to values for 100% NRC 
ewes (Table 3.4).  Concentrations of aspartate, serine and alanine in serum also 
increased (P < 0.05) in the 50% NRC + Arg group to concentrations comparable 
to those for control ewes (Table 3.4). 
  Except for asparagine, serine, histidine, -alanine, alanine and 
methionine, concentrations of amino acids in maternal serum varied with day of 
pregnancy (Table 3.4).  The most striking changes were observed for glutamate 
and threonine, whose concentrations progressively decreased (P < 0.01) by 
71% and 48%, respectively, between Days 60 and 140 of gestation.  In contrast, 
concentrations of glutamine, isoleucine, taurine and lysine increased (P < 0.05) 
by 95%, 63%, 138%, and 65%, respectively in maternal serum, between Days 
60 and 140 of gestation.  Levels of cysteine in maternal serum also increased 
between Days 60 and 80 of pregnancy, but subsequently decreased gradually 
until Day 140 of gestation. In addition, there was a treatment x day interaction (P 
< 0.05) for aspartate, citrulline, arginine, alanine, valine, isoleucine, lysine, 
cysteine and proline in that concentrations in serum at Day 60 of gestation were 
lower (P < 0.05) in both the 50% NRC and the 50% NRC + Arg ewes compared 
to values for control-fed ewes.  At Day 140 of pregnancy, concentrations of 
aspartate, arginine, valine, isoleucine, lysine and cysteine in serum of the 50% 
NRC +Arg ewes were comparable to those in control-fed ewes (Table 3.5).  
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Concentrations of other metabolites and hormones in maternal serum 
 Undernourished ewes (with and without arginine infusion) had lower (P < 
0.01) concentrations of glucose in serum than control-fed ewes (Table 3.6), but 
there was no effect of day of pregnancy (Table 3.6).  Interestingly, levels of 
triglycerides in serum were 34% lower (P < 0.05) and those of free fatty acids 
were greater (P < 0.05) in 50% NRC + Arg ewes than in both the 50% NRC and 
100% NRC ewes (Table 3.6).  Intravenous infusion of arginine reduced (P < 
0.05) concentrations of ammonia in serum from underfed ewes, but had no 
effect on those of β-hydroxybutyrate, glucose, lactate, urea, insulin, or growth 
hormone. 
Concentrations of β-hydroxybutyrate, free fatty acids, glycerol, 
triglycerides, and growth hormone increased (P < 0.01), while concentrations of 
insulin decreased (P < 0.01), in ewes between Days 60 and 140 of gestation 
(Table 3.6).  Day of pregnancy had no effect on concentrations of glucose, urea, 
or ammonia in maternal serum.  Among all metabolites and hormones 
measured, only glycerol and growth hormone were affected by a treatment X 
day interaction (P = 0.05, Tables 3.4 and 3.5). 
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Table 3.4.  Concentrations (µM) of amino acids in maternal serum on Days 60, 80, 110 and 140 of pregnancy in control-fed (100% NRC), and underfed  
ewes (50% NRC) with or without arginine infusion (155 mol/kg body weight, three times daily) 
 Treatment (T)   Day (D)    P values 
Amino acid 
 
100% 
NRC 
50% 
NRC 
50% 
NRC+ Arg  60 80 110 140  
SEM 
 T D T*D 
Aspartate 
      7.9a      4.6b      6.0ab        5.6b      7.3a     5.6b     6.1ab    0.9    0.014   0.044 0.029 
Glutamate 
  120    93    98   177a  106b   81c   51d  13    0.086 <0.0001 0.494 
Asparagine 
    30a    18b    23b     25    25   24   20    4    0.001   0.331 0.685 
Serine 
    79a    58b    71ab     72    76   69   61    8    0.049   0.101 0.186 
Glutamine 
  232  173  193   125b  202a 226a 244a  22    0.070 <0.0001 0.099 
Histidine 
    43a    27b    34b     35    37   31   35    4    0.003   0.282 0.804 
Glycine 
  394  381  442   362b  379b 409ab 472a  58    0.548   0.042 0.451 
Threonine 
  105a    28b    36b     71a    65a   53ab   37b  14  <0.0001   0.008 0.097 
Citrulline 
  261a  159b  190b   182b  267a 186b 179b  24    0.0009   0.0002 0.039 
Arginine 
  295a  178b  300a   204c  301a 265b 262b  26    0.0005   0.0001 0.004 
-Alanine 
    13     7.9     9.4       9.8      9.9    9.8   11    2    0.057   0.704 0.526 
Taurine 
  142a    77b    92b     48c  144a 110b 113b  17    0.0002 <0.0001 0.759 
Alanine 
  178a  118b  149ab   148  163 133 149  16    0.010   0.055 0.015 
Tyrosine 
    52a    27b    33b     33b    41a   36ab   40a    4    0.0001   0.013 0.537 
Tryptophan 
    40a    22b    26b     30b    38a   27b   21c    3  <0.0001 <0.0001 0.177 
Methionine 
    17a     7.5c    10b     11    11   12   12    2  <0.0001   0.413 0.468 
Valine 
  162a    77b  106b   117a  140b 101a 102a  15    0.0002   0.001 0.013 
Phenylalanine 
    46a    28b    36b     28b    38a   38a   44a    4    0.002   0.0003 0.650 
Isoleucine 
    81a    51c    70b     51c    65b   70b   84a    6    0.0006 <0.0001 0.033 
Leucine 
  126a    75c  102b     82c  115a   98b 109ab  11    0.002   0.0008 0.451 
Ornithine 
  108a    42c    65b     64b  102a   66b   55b  11    0.0006 <0.0001 0.261 
Lysine 
  127a    69b    89b     62b  113a 101a 103a  31    0.0005 <0.0001 0.028 
Cysteine 
  167a  112c  133b   121c  180a 135b 113d    6  <0.0001 <0.0001 <0.0001 
Proline 
  145a    95c  123b   115b  122a  122a  125a    6  <0.0001    0.006 <0.0001 
Data are means with pooled SEM, n = 15 observation per day (5 ewes x 3 treatments) and n = 20 observations per treatment (5 ewes x 4 days).  Values sharing different 
superscripts within a row differ due to effects of treatment (T), day (D) or treatment x day (T*D) interaction based on two-way ANOVA for repeated measures and the 
Student-Newman-Keuls multiple comparisons test. 
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Table 3.5.  Concentrations of amino acids, glycerol and GH in serum of control-fed (100% NRC) and underfed ewes (50% NRC) with or without  
intravenous arginine infusion (155 mol/Kg body weight, three times daily) 
            
 Day 60   Day 80   Day 110   Day 140  
AA 
and 
Metab 
100% 
NRC 
50% 
NRC 
50% 
NRC+ 
Arg 
SEM  100% NRC 
50% 
NRC 
50% 
NRC+ 
Arg 
SEM  100% NRC 
50% 
NRC 
50% 
NRC+ 
Arg 
SEM  100% NRC 
50% 
NRC 
50% 
NRC+ 
Arg 
SEM 
Asp (M) 7.8ª 4.7b 4.3b 0.7  9.6 7.6 7.0 1  5.9 6.0 5.5 0.9  8.8a 3.1b 7.2a 1.1 
Cit (M) 284ª 127b 129b 18  362ª 197b 241b 28  225 148 180 20  160 155 203 37 
Arg (M) 287ª 150b 181b 26  327a 186b 368a 23  274a 212b 322c 12  259a 175b 327a 30 
Ala (M) 195ª 120b 127b 13  158 167 183 23  154 126 133 11  198a 106b 144b 11 
Val (M) 187a 74b 88b 13  200 105 123 25  142a 63b 94b 10  132a 69b 115a 14 
Ile (M) 73ª 40b 41b 5  70a 47b 75a 6  81a 56b 73a 4  99a 63b 92a 7 
Lys (M) 110a 35b 44b 7  154 94 100 19  128a 74c 103b 8  127a 72b 115a 13 
Cys (M) 161a 105b 96b 6  218a 150c 173b 7  162a 105c 139b 7  127a 88b 124a 4 
Pro (M) 147a 96b 102b 7   142a   95b 128a 5  142a 92b 132a 5  149a 97c 130b 5 
Glycerol 
(M) 22 33 38 8  18 28 38 8  28 25 48 7  14
a
 3.6c 8.6b 1.6 
GH 
(ng/ml) 3.0 2.8 2.4 0.4  2.8 2.7 3.0 0.5  3.1 3.1 4.1 0.6  7.0 12, 5.7 1.8 
Data are means ± pooled SEM for 5 ewes per treatment group.  On each Day of gestation, values sharing different superscripts within a row differ (P < 0.05), as analyzed 
by one-way ANOVA and the Student-Newman-Keuls multiple comparisons test. 
AA = amino acids, Metab = other metabolites, GH = Growth Hormone 
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Table 3.6.  Concentrations of metabolites and hormones in serum on Days 60, 80, 110 and 140 of pregnancy in control fed  
(100% NRC), and underfed ewes (50% NRC) with or without arginine infusion (155 mol/kg body weight, three times daily) 
               
Metabolite Treatment (T) means  Day (D) means  SEM  P values 
 
100% 
NRC 
50% 
NRC 
50% 
NRC+ Arg  60 80 110 140   
 T D T*D 
BHB (mM) 
   1.1    1.4    1.1      0.7b     0.9b     1.5a     1.5a      0.3  0.323   0.0007 0.202 
FFA (µM) 319b 411b 589a  236c 340bc 404b 777a  114  0.038 <0.0001 0.413 
Glucose (mM) 
   2.5a    2.1b    1.9b      2.3     2.2     2.0     2.1      0.2  0.010 0.285 0.559 
Glycerol (M) 
  49  29  54    30b   28b   34b   84a    14  0.093   0.0002 0.046 
Lactate (mM) 
   1.5    1.0    1.0      1.9a     1.2b     0.8b     0.9b      0.3  0.130 <0.0001 0.151 
Triglycerides (M) 161a 157a 106b  135b 113b 140b 178a    21  0.030 0.004 0.466 
Urea (mM) 
   5.8    4.7     4.6      5.5     5.0     4.6     5.0      0.6  0.098 0.158 0.119 
Ammonia (µM) 
  91ab 103a   85b    96   92   91   93      6.0  0.067 0.353 0.317 
Insulin (ng/L) 528 322 533  669a 564a 333b 277b  134  0.267 0.003 0.884 
GH (ng/ml) 
   3.8    5.0    3.6      2.7b     2.9b     3.4b     7.5a      1.0  0.213 <0.0001 0.051 
Data are means with pooled SEM, n = 15 observation per day (5 ewes x 3 treatments) and n = 20 observations per treatment (5 ewes x 4 days).  Values 
sharing different superscripts within a row differ due to effects of treatment (T), day (D) or T*D interaction, as analyzed by two-way ANOVA for repeated 
measures and the Student-Newman-Keuls multiple comparisons test. 
BHB= -Hydroxybutyrate, FFA= Free Fatty Acids, GH= Growth Hormone 
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Discussion 
 Despite advanced technologies for prenatal care of both mothers and 
fetuses, IUGR remains a global health problem that causes significant perinatal 
complications and may contribute to adult-onset diseases (Murphy et al., 2006).  
Since there is currently a lack of therapeutic treatment for IUGR in humans (Mari 
& Hanif, 2007),  animal models are used to test novel hypotheses in research 
that will provide the bases for development of effective therapies (Luther et al., 
2005).  Although there are several basic differences in pregnancy between 
sheep and humans, including time of implantation, type of placentation, and 
gestational length (Leiser & Kaufmann, 1994), the ewe is a well-established 
animal model for studying human placental-transfer of nutrients to the fetus for 
several reasons (Wallace et al., 2005):  First, the number of offspring and 
regulation of nutrient transfer from mother to fetus are similar between ewes and 
women (Battaglia & Regnault, 2001).  Second, ewes can be conveniently 
managed for easy access to blood and other sample collection.  Third, pregnant 
ewes are tolerant of surgical procedures that include placement of catheters into 
maternal and fetal blood vessels without aborting (Caton et al., 1983).  Fourth, 
there is a large database in the literature on placental and fetal development in 
normal and underfed ewes (Mellor, 1983; Reynolds & Redmer, 1995). 
 Among intrauterine environmental factors, nutrition plays the most 
decisive role in influencing placental and fetal growth (Wu et al., 2004a).  In fact, 
well-controlled animal studies have consistently demonstrated that maternal 
undernutrition during a critical period of pregnancy substantially reduces birth 
weight at term (Osgerby et al., 2002).  Although enteral re-feeding to 100% of 
NRC-recommended nutrient requirements is potentially effective to reverse 
IUGR caused by undernutrition (Kwon et al., 2004a), this means of intervention 
is not applicable under clinical conditions such as hyperemesis gravidarum, 
which is characterized by severe nausea and vomiting in gestating women (Snell 
et al., 1998).  This life-threatening disorder occurs in 1-2% of all pregnancies and 
  
60 
generally extends beyond the 16th week of gestation (Attard et al., 2002).  
Therefore, parenteral nutrition must be explored to improve pregnancy outcome 
in these women.  Through bypassing intestinal catabolism (Wu, 1995), direct 
intravenous infusion of arginine into dams may effectively increase its 
concentrations in maternal and fetal blood of underfed ewes.  Consistent with 
this proposition, maternal and fetal concentrations of arginine in serum were 
increased by 170% and 40%, respectively after an infusion of a large dose of 
arginine (695 µmol/kg body weight over 280 min ) into the femoral vein of well-
fed sheep (Thureen et al., 2002).  Further, in an ovine model of IUGR induced 
by placental embolization, infusion of arginine into the fetal femoral vein 
increased fetal whole-body protein accretion (De Boo et al., 2005).  However, 
these studies involved short-term (3 to 4 h) infusion of arginine into ewes or 
fetus, so the effects of arginine on fetal growth could not be evaluated. 
 Birth weight is one of the most sensitive and important measures of fetal 
growth (Redmer et al., 2004).  Consistent with previous reports (Vonnahme et 
al., 2003; Kwon et al., 2004a; Satterfield et al., 2007), results from the current 
study indicated that global nutrient restriction (50% of NRC requirements) 
beginning on Day 28 of gestation resulted in IUGR (Table 3.3).  In addition, 
marked reductions in concentrations of most amino acids (Table 3.4) and 
glucose (Table 3.6) were detected in maternal serum.  Thus, ewes subjected to 
severe malnutrition were not able to maintain homeostasis of amino acids for 
normal fetal growth.  A novel and important finding of the present study is that 
intravenous infusion of arginine to underfed ewes (155 µmol arginine-HCl per kg 
body weight) three times daily between Day 60 of pregnancy and parturition 
effectively prevented IUGR, without affecting maternal body weight (Table 3.3).  
This indicates that the arginine treatment enhanced the availability of nutrients to 
the conceptus to support fetal growth.  Indeed, concentrations of several 
essential and conditionally essential amino acids (methionine, isoleucine, 
leucine and cysteine) were higher in serum of arginine-treated than in saline-
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infused underfed ewes (Table 3.4).  Moreover, concentrations of some non-
essential amino acids (aspartate, serine and alanine) in serum of arginine-
treated underfed ewes were comparable to those for control-fed ewes (Table 
3.4).  In addition, concentrations of proline, a neutral amino acid that has been 
recently suggested to have an important role in conceptus metabolism and 
development (Wu et al., 2008), were 29% higher in arginine-treated than in 
saline-underfed ewes.  Because all underfed ewes had the same intake of 
nutrients, including protein (Table 3.2), the higher concentrations of amino acids 
in serum from arginine-treated ewes compared to the saline-infused underfed 
ewes may have resulted from alterations in maternal nitrogen metabolism.  In 
support of this view, there is evidence that NO reduces the urea cycle activity 
and the oxidation of amino acids in hepatocytes (Jobgen et al., 2006).    
 Increasing concentrations of arginine in maternal plasma by 69% can 
enhance NO synthesis by endothelial cells (Wu & Meininger, 2002) and utero-
placental blood flow (Neri et al., 1995).  This, in turn, would be expected to 
promote the transfer of oxygen and nutrients from maternal to fetal circulations.  
Consistent with this theory, intramuscular administration of Sildenafil citrate to 
underfed ewes between Days 28 and 112 of gestation increased concentrations 
of most amino acids and polyamines in fetal plasma and fluids, as well as fetal 
growth (Satterfield et al., 2007).  Sildenafil citrate, which acts through enhancing 
intracellular cGMP availability by inhibiting phosphodiesterase-5 (an enzyme that 
hydrolyzes cGMP), may have augmented utero-placental blood flow via the 
protein kinase G signaling pathway (Wareing et al., 2005).  Because 
catheterization of fetal vessels for blood sampling could affect fetal growth, we 
chose not to perform this invasive procedure in the present study.  Therefore, 
precise changes in concentrations of nutrients in fetal circulation as well as 
amniotic and allantoic fluids due to intravenous infusion of arginine into ewes 
were not determined.  Additional studies are warranted to test the hypothesis 
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that parenteral administration of arginine may increase utero-placental blood 
flow and, thus, the supply of nutrients from mother to fetus. 
 The changes in maternal serum concentrations of hormones and 
metabolites observed with advanced gestation and arginine infusion in this study 
deserve comments (Table 3.6).  In contrast to a large pharmacological bolus of 
arginine (2 mmol/kg body weight) (Davis, 1972), intravenous infusion of a 
physiological dosage of arginine (155 µmol/kg body weight three times daily) 
had no effect on circulating levels of insulin or growth hormone (Table 3.6).  
However, there were progressive increases in concentrations of free fatty acids, 
glycerol and -hydroxybutyrate in maternal serum during late gestation (Table 
3.6).  These results indicate mobilization of maternal fat stores to provide energy 
for maternal and fetal metabolism and are consistent with the progressive 
decrease in concentrations of insulin (an anti-lipolytic hormone) (Owens, 1991) 
and the progressive increase in concentrations of growth hormone (a lipolysis-
enhancing hormone) (Owens, 1991) in maternal serum between Days 60 and 
140 of gestation (Table 3.6).  In addition, concentrations of triglycerides were 
lower, but concentrations of free fatty acids were higher, in serum of arginine-
treated ewes than saline-infused underfed or control-fed ewes (Table 3.6). Of 
particular interest, physiological levels of NO stimulate the hydrolysis of 
triglycerides in adipose tissue (Fu et al., 2005), thereby increasing the availability 
of circulating free fatty acids for oxidation by maternal tissues (e.g., skeletal 
muscle) as metabolic fuels (Jobgen et al., 2006).   This, in turn, can spare the 
oxidation of amino acids, which may have contributed to elevated levels of some 
amino acids in maternal serum of arginine-treated underfed ewes (Table 3.4). In 
support of this suggestion, concentrations of ammonia were lower in serum of 
underfed ewes in response to intravenous infusion of arginine (Table 3.6).   
 In conclusion, parenteral administration of arginine to underfed ewes 
increased concentrations of arginine and related amino acids in maternal serum 
and prevented fetal growth restriction.  These novel findings provide an 
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experimental basis for the clinical use of arginine to eliminate or ameliorate 
IUGR in humans.  The results also provide a new framework for studies of 
molecular mechanisms responsible for beneficial effects of arginine in regulating 
conceptus growth and development. 
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CHAPTER IV 
PARENTERAL ADMINISTRATION OF ARGININE TO EWES CARRYING 
MULTIPLE FETUSES ENHANCES FETAL SURVIVAL AND BIRTH WEIGHTS 
OF QUADRUPLETS  
 
Introduction 
Uterine capacity is a major factor limiting fetal survival and growth in 
mammals (Wu et al., 2006; Gootwine et al., 2007).  This maternal constraint is 
particularly evident in women or ewes carrying multiple fetuses, where demand 
for nutrients and space to nurture all fetuses cannot be adequately met 
(Gluckman & Hanson, 2004).  Indeed, an inverse relationship between the 
number of fetuses and birth weight has been described for humans (Blickstein & 
Kalish, 2003; Blickstein, 2005) and other mammals (Wootton et al., 1983; Freetly 
& Leymaster, 2004; Gootwine et al., 2007).  
With the advancement of assisted reproductive technologies, the 
frequency of twins and higher-order multiple fetuses has markedly increased in 
human pregnancies over the past 2 decades (Blickstein, 2005).  This translates 
into a greater proportion of premature and low birthweight infants in the United 
States of America and elsewhere (Fliegner, 1989; Siddiqui & McEwan, 2007).  In 
addition, genetic selection and breeding in sheep has resulted in new breeds 
with increased litter size (up to 6 fetuses per ewe), but greatly reduced birth 
weights and survival of lambs (Gootwine et al., 2007).  However, there are no 
current treatments for preventing fetal growth restriction (IUGR) in humans or 
sheep gestating multiple fetuses.  We have suggested that this problem may be 
ameliorated by modulation of the placental nitric oxide- and polyamine-synthetic 
pathways, thus impacting utero-placental blood flow and perhaps direct actions 
on the fetus (Wu et al., 2004a).  In support of this notion, Mateo et al. (2007) 
recently reported that supplementing arginine (a common substrate for the 
synthesis of nitric oxide and polyamines) to the gestation diet for gilts (a litter-
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bearing species) increased the number and litter weight of live-born piglets by 
22% and 24%, respectively.  On the basis of these findings, we hypothesized 
that parenteral administration of arginine may enhance fetal survival and growth 
in pregnancies with multiple fetuses.  This hypothesis was tested with prolific 
Booroola Rambouillet ewes.   
 
Materials and methods 
Ewes  
Multiparous Booroola Rambouillet ewes (FecB+/-) (n=41) with a body 
weight of 68.4 ± 1.4 kg (mean ± SEM) were bred to fertile Booroola Rambouillet 
rams (FecB+/-) fitted with marking harnesses.  In order to minimize paternal 
genetic effects on size and weight of the fetuses, the same two rams were used 
throughout the breeding period.  Breeding dates were determined by daily 
inspection of crayon marks on lumbar region of the ewes.  The color of the 
marking crayon was changed every 15 days to detect return to estrus.  The day 
of first observation of a color mark on the dam was considered as the first day of 
estrus and of pregnancy (Day 0).  Pregnancy diagnosis and initial fetal counts 
were conducted by transabdominal ultrasonography at Day 35 post-mating (7.5 
MHz probe, Aloka Inc. console).  Ewes that were confirmed pregnant and 
carrying twins, triplets or quadruplets were sheared and housed in outdoor pens 
from Day 40 until parturition.  To confirm that ewes were gestating multiple 
fetuses and to reassess initial counts of fetal numbers, a second transabdominal 
ultrasonography was performed at Day 45.  During the first two thirds of 
pregnancy, ewes were individually housed in covered pens with cement floors.  
In the last third of gestation, collective partially-covered dirt-floor pens were 
used.  Throughout pregnancy, ewes had free access to drinking water and were 
fed a corn, soybean, rice and alfalfa-based diet (Producers Cooperative 
Association, Bryan, TX, USA) to meet 100% of the National Research Council 
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(NRC)-recommended maintenance requirements for pregnant ewes gestating 
multiple fetuses (NRC, 1985).  The dietary composition is shown in Table 4.1.   
 
 
 
Table 4.1. Exp. 3/ Composition of the diet (as-fed basis)1 
Ingredients 
 
Content 
Corn  37.45% 
Soybean hulls  32.65% 
Soybean meal  10% 
Rice bran  5% 
Dehydrated alfalfa  5% 
Rice mill feed  4.25% 
Liquid binder  2.5% 
Soy oil  1.8% 
Ground limestone  0.25% 
Sodium bicarbonate  0.50% 
Mineral mixture  0.50% 
Vitamin mixture  0.10% 
1Nutrients provided in the diet were: 12.5% crude protein; 0.74% arginine; 5.5% crude fat; 15% 
crude fiber; 0.91% sodium; 0.49% calcium; 0.36% phosphorus; 1.02% potassium; 0.91% 
chloride; 0.17% sulfur; 0.22% magnesium; 140.09 ppm manganese; 117.76 ppm iron; 12.4 ppm 
copper; 0.28 ppm cobalt; 136.75 ppm zinc; 1.01 ppm iodine; 0.16 ppm selenium; 1.00 ppm 
molybdenum; 5,698 IU/kg vitamin A; 11.1 IU/kg vitamin E; and 454.5 IU/kg vitamin D. 
 
 
 
During the first two thirds of pregnancy, the given amount of feed was 
provided in two equal rations at 0700 h and 1500 h and adjusted on an individual 
basis weekly, according to live-weight changes of ewes. In the last third of 
gestation (from week 15), the feed was provided ad libitum to ensure adequate 
intake of nutrients.  The amounts of feed intake over the experimental period are 
summarized in Table 4.2.  This study was approved by the Texas A&M 
University Institutional Animal Care and Use Committee. 
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Table 4.2. Feed intake (g/kg body weight per day) over the experimental period in 
control or arginine-HCl infused ewes  
 Feed intake 
Week of pregnancy Control Arginine 
6 17.3 ± 0.22c 17.5 ± 0.37e 
7 17.5 ± 0.30c 17.5 ± 0.30e 
8 17.6 ± 0.37c 17.5 ± 0.35e 
9 17.2 ± 0.31c 17.4 ± 0.33e 
10 17.2 ± 0.29c 17.1 ± 0.30fe 
11 16.7 ± 0.26dc 16.7 ± 0.27fg 
12 16.5 ± 0.26d 16.8 ± 0.28fg 
13 16.5 ± 0.22d 16.5 ± 0.25g 
14 16.1 ± 0.24d 16.2 ± 0.26g 
15 25.8 ± 0.43a 26.2 ± 0.57a 
16 25.7 ± 0.46a 25.2 ± 0.44b 
17 24.8 ± 0.34b 24.6 ± 0.35c 
18 24.8 ± 0.50b 24.3 ± 0.40cd 
19 24.8 ± 0.49b 24.6 ± 0.44c 
20 24.1 ± 0.55b 24.2 ± 0.52cd 
21 24.8 ± 0.71b 23.9 ± 0.52d 
Data are means ± SEM. Values sharing different superscripts within a column differ (P < 0.05). 
 
 
 
Experimental design 
At Day 100 of pregnancy, ewes were assigned randomly to receive an 
intravenous infusion of either sterile saline (control group, n=14; approximately 
15 ml of 0.9% sodium chloride, Hospira Inc. Lake Forest, IL) or the same volume 
of sterile L-arginine-HCl-saline (arginine group, n=20; Sigma-Aldrich Co., St 
Louis MO, USA; 345 µmol arginine/kg body weight) three times per day until 
Day 121 of pregnancy.  The L-arginine-HCl solution was prepared three times 
per week, using sterile physiologic saline (0.9% sodium chloride, Hospira Inc, 
Lake Forest, IL, USA) with a final concentration of 1.5 g arginine per 5 ml.  The 
pH was adjusted to 7.0 with 1 M NaOH and the solution passed through 0.22 m 
cellulose acetate filters (Corning Inc, NY, USA) into reusable sterile glass 
containers fitted with adjustable sealing sterile rubber caps.  The prepared L-
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arginine-HCl solution was stored at -20°C and thawed at 4°C the night before 
being used.  Disposable 20 ml syringes (latex free, luer-lok tip, Becton 
Dickinson, Franklin Lakes, NJ, USA) were marked with ewe identification 
numbers and filled in the laboratory with either saline solution or L-arginine-HCl 
solution before each infusion.  A bacteriological culture of randomly selected 
saline and arginine solutions was performed by the Texas Veterinary Medical 
Diagnostic Laboratory (College Station, TX) on two occasions to verify sterility.  
To administer the saline and L-arginine-HCl solutions, sterile 21 G X ¾” (0.80 X 
19 mm) disposable winged infusion sets (SURFLO, Terumo Medical 
Corporation, Elkton, MD, USA) were used.  An extra 0.5 ml volume of solution 
was considered when calculating the total volume to be infused, allowing for 
losses remaining inside the infusion set tubing after injection.  To minimize 
damage to tissues due to frequent insertion of the infusion set needles that was 
required for repeated daily administration of solutions, care was taken to 
alternate jugular veins and to change sites of penetration. 
At Days 100, 115 and 140 of pregnancy, blood samples were collected, 
immediately before the administration of saline or L-arginine-HCL solutions, to 
measure concentrations of amino acids, other metabolites, and hormones in 
maternal serum.  On Day 121, samples were drawn at 1 h after the solutions 
were infused to determine changes in circulating levels of hormones, amino 
acids, and other metabolites in response to either infusion.  Anticoagulant-free, 
sterile, 10 ml vacuum tubes (Vacutainer, Becton Dickinson, Franklin Lakes, NJ) 
were used for blood collection.  Blood samples were placed on ice and 
immediately centrifuged at 3,000 x g for 15 min.  Serum was obtained and 
stored at -80°C until analysis.   
At parturition, a portable scale was used to obtain and record the weight 
of each lamb at birth.  Care was taken to weigh the lambs immediately after 
birth.  
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Determination of concentrations of amino acids, other metabolites, and 
hormones in maternal serum 
Deproteinated serum was used for the analysis of amino acids, ammonia, 
urea, glucose, lactate, glycerol, and -hydroxybutyrate (BHB), whereas whole 
serum was assayed for free fatty acids (FFA), triglycerides, insulin and growth 
hormone (GH).  Amino acids were determined by fluorometric HPLC methods 
involving precolumn derivatization with o-phthaldialdehyde as previously 
described (Wu et al., 1997).  -Hydroxybutyrate was measured enzymatically by 
a spectrophotometric method using 3-hydroxybutyrate dehydrogenase (Wu et 
al., 1991).  Free fatty acids were quantified by an enzymatic colorimetric method 
using the NEFA-HR (2) assay kit from Waco Chemicals Inc. (Richmond, VA, 
USA).  Glucose was determined enzymatically using a spectrophotometric 
method involving hexokinase and glucose-6-phosphate dehydrogenase (Fu et 
al., 2005).  Glycerol and L-lactate were quantified using enzymatic fluorometric 
methods as described (Wu et al., 1991; Fu et al., 2005).  Triglycerides were 
determined enzymatically using the InfinityTM assay kit from Thermo Electron 
Corporation (Pittsburgh, PA, USA).  Ammonia and urea were determined by 
fluorometric methods involving glutamate dehydrogenase and urease (Wu, 
1995; Wu et al., 1995).  Insulin was analyzed using the ovine insulin ELISA 
microplate kit from Mercodia AB (Uppsala, Sweden), whereas GH was 
quantified by RIA (Powell & Keisler, 1995; Lalman et al., 2000) validated for 
ovine serum. 
 
Statistical analyses 
Data on lamb birthweight were statistically analyzed by one-way ANOVA, 
with litter size nested within treatment (Steel et al., 1997).  Data on 
concentrations of amino acids, other metabolites, and hormones in serum on 
Days 100, 121 and 140 of pregnancy in control ewes was analyzed by two-way 
ANOVA for repeated measures to determine the effects of day, litter size, and 
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their interaction.  Concentrations of amino acids, other metabolites, and 
hormones in maternal serum on Day 121 of pregnancy in the arginine group 
were compared by two-way ANOVA considering the effects of treatment, litter 
size and their interaction.  Log transformation of variables was performed when 
the variance of data was not homogenous among treatment groups, as 
assessed by the Levene’s test.  Differences in numbers of live and dead fetuses 
between treatment groups were evaluated by Chi-square analysis. All analyses 
were performed using the statistical package SAS (version 9.1, SAS Institute, 
Cary, NC, USA).  P values  0.05 were taken to indicate statistical significance.  
 
Results 
Body weight of ewes 
 Maternal body weight increased (P < 0.05) progressively between weeks 
10 and 19 of gestation, but did not differ (P > 0.05) between saline- and 
arginine-infused ewes during the experimental period (Table 4.3).  Body weights 
of saline- and arginine-treated ewes were also similar (P > 0.05) immediately 
after parturition (70.1 ± 3.3 and 69.2 ± 2.4 kg, respectively). 
 
Percentage of lambs born alive 
There were twin, triplet and quadruplet pregnancies in both control and 
arginine-treated ewes.  The control ewes had three twin, seven triplet and four 
quadruplet pregnancies, while the arginine ewes had seven twin, five triplet and 
eight quadruplet pregnancies.  A number of ewes in this study presented clinical 
signs of ketosis and delivered stillborn lambs. The percentages of lambs born 
alive were 27.9% and 44.3%, respectively, for control and arginine-treated ewes 
(Table 4.4).  Infusion of arginine did not affect the total number of lambs born per 
ewe.  However, the arginine treatment reduced (P < 0.05) the percentage of 
lambs born dead by 23%, while enhancing (P = 0.05) the percentage of lambs 
born alive by 59% (Table 4.4).  
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Table 4.3. Body weights of control and arginine-infused 
ewes from weeks 6 to 21 of pregnancy 
Body weight of ewes 
(means ± SEM) Control arginine 
Week of 
pregnancy 
  6 68.2 ± 1.5 k 68.8 ± 2.2k  
7 67.0 ± 1.7k  66.5 ± 2.0k 
8 67.8 ± 1.9k 67.2 ± 2.0jk 
9 69.0 ± 1.8jk  68.6 ± 2.0ij 
10 70.8 ± 1.7ij 70.6 ± 1.9hi 
11 72.5 ± 1.9hi 72.6 ± 2.0gh 
12 74.1 ± 1.8gh 73.7 ± 1.9fg 
13 75.6 ± 1.8fg 75.2 ± 1.9ef 
14 76.5 ± 1.6ef 76.5 ± 1.9de 
15 77.8 ± 1.5e 78.1 ± 1.9d 
16 81.1 ± 1.7d 81.6 ± 2.0c 
17 83.5 ± 1.6c 84.3 ± 2.1b 
18 83.4 ± 2.1c 85.2 ± 2.3b 
19 85.6 ± 2.2bc 87.6 ± 2.5a 
20 86.9 ± 3.0ab 87.7 ± 2.9a 
21 86.8 ± 3.8ab 89.9 ± 3.5a 
Data are means ± SEM. Values sharing different superscripts within a 
column differ (P < 0.05). 
 
 
 
Table 4.4.  Number of lambs born alive and dead from control and arginine-
infused ewes 
  
 
 
  
 
 
Litter size  
 
 twins triplets quadruplets  Total Treatment Status at birth 
  
 
   
% of total 
lambs born 
per group 
Arginine alive      14      6         7  27       44.3 † 
 dead        0      9       25  34       55.7 ‡ 
 total      14    15       32  61        
         
Control alive       3      8         1  12      27.9 
 dead       3    13       15  31      72.1 
 total       6    21       16  43  
† P = 0.05 and ‡ P < 0.05 vs the control group.
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Birth weights of lambs 
The birth weights of twins were greater (P < 0.02) than those of triplets 
and quadruplets within each treatment group (Table 4.5).  In addition, newborn 
triplets were heavier than quadruplets in saline-infused ewes (P = 0.038), but not 
in arginine-infused dams (P = 0.175).  There were no differences (P > 0.05) in 
birth weights of twin or triplet lambs between control and arginine-treated ewes 
(Table 4.5).  However, arginine infusion increased (P < 0.05) the birth weights of 
quadruplet lambs by 23% (P < 0.05), when compared with counterparts born to 
control ewes (Table 4.5).  
 
 
 
Table 4.5.  Birth weights of lambs from twin, triplet and quadruplet pregnancies  
from control and arginine-infused ewes  
Birth weight of lambs 
(kg) Group 
Twins  triplets  quadruplets 
Control 4.30 ± 0.38 a  3.06 ± 0.17 b  2.47 ± 0.22 c 
Arginine infused 4.11 ± 0.21 a  3.39 ± 0.22 b  3.03 ± 0.14 b 
Data are means ± SEM.  a-b: Means sharing different superscripts within a row or a column 
differ (P < 0.05). 
 
 
 
Concentrations of amino acids in maternal serum 
Concentrations of amino acids in maternal serum at 1 h after arginine or 
saline infusions on Day 121 of pregnancy are summarized in Table 4.6.  
Circulating levels of arginine, ornithine, cysteine and proline increased (P < 0.01) 
by 183%, 286%, 32% and 44% respectively, in arginine-infused ewes, when 
compared with saline-infused dams.  In contrast, concentrations of asparagine, 
-alanine, alanine, tyrosine, methionine, valine, phenylalanine and isoleucine 
were lower (P < 0.05) in arginine-infused than in saline-infused ewes.  Litter size 
affected concentrations of glycine, threonine and citrulline in maternal serum on  
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Table 4.6.  Concentrations of amino acids in serum in arginine-treated (345 mol/kg body weight) and control ewes 
at one hour after infusion on Day 121 of pregnancy 
 Treatment group   Litter size  
Amino acid 
 Arginine Control P values  Twins Triplets Quadruplets P value 
Aspartate 
     5.1 ± 0.4    4.3 ± 0.5  0.18      5.3 ± 0.6    4.3 ± 0.5    4.4 ± 0.5 0.34 
Glutamate 
 108 ± 4 108 ± 5  0.96  112 ± 6 108 ± 5 104 ± 6 0.64 
Asparagine 
   22 ± 2 b   29 ± 2 a  0.03    26 ± 3   25 ± 2   26 ± 2 0.98 
Serine 
   67 ± 3   66 ± 4  0.87    71 ± 5   68 ± 4   62 ± 4 0.39 
Glutamine 
 135 ± 5 136 ± 7  0.96  140 ± 8 136 ± 7 130 ± 7 0.64 
Histidine 
   31 ± 2   37 ± 3  0.13    38 ± 4   28 ± 3   37 ± 3 0.06 
Glycine 
 339 ± 21 342 ± 26  0.93  408 ± 31 a 320 ± 26 b 294 ± 28b 0.03 
Threonine 
   54 ± 7   71 ± 9  0.13    85 ± 11 a   42 ± 9 b   60 ± 9 ab 0.02 
Citrulline 
 103 ± 10 114 ± 13  0.52  142 ± 15 a   93 ±13 b   90 ± 14 b 0.03 
Arginine 
 422 ± 24 a 149 ± 30 b   <0.01  273 ± 37 279 ± 31 304 ± 33 0.79 
-Alanine 
     8.3 ± 0.7 b   12 ± 0.9 a   <0.01     9.9 ± 1    9.5 ± 0.9   12 ± 1 0.29 
Taurine 
 110 ± 9   99 ± 11  0.41  102 ± 13 100 ± 11 112 ± 12 0.73 
Alanine 
 122 ± 10 b 157 ± 12 a  0.03  133 ± 14 162 ± 12 124 ± 13 0.10 
Tyrosine 
   41 ± 5 b   70 ± 6 a   <0.01    48 ± 8   68 ± 7   50 ± 7 0.08 
Tryptophan 
   24 ± 2   28 ± 3  0.23    28 ± 3   26 ± 3   24 ± 3 0.61 
Methionine 
   10 ± 1 b   15 ± 1 a   <0.01    12 ± 2   12 ± 1   13 ± 1 0.84 
Valine 
   71 ± 8 b   97 ± 10 a  0.04    90 ± 12   75 ± 10   87 ± 11 0.61 
Phenylalanine 
   27 ± 2 b   37 ± 3 a   <0.01    33 ± 3   28 ± 3   34 ± 3 0.29 
Isoleucine 
   46 ± 4 b   68 ± 5 a   <0.01    51 ± 6   58 ± 5   61 ± 6 0.52 
Leucine 
   74 ± 7   92 ± 9  0.10    82 ± 10   73 ± 9   95 ± 9 0.23 
Ornithine 
 165 ± 12 a   43 ± 15 b   <0.01  130 ± 19   84 ± 16   98 ± 16 0.18 
Lysine 
   88 ± 7   89 ± 9  0.91    88 ± 10   80 ± 9   98 ± 9 0.38 
Cysteine 
 115 ± 4 a 87 ± 5 b   <0.01  109 ± 6   99 ± 5   96 ± 5 0.24 
Proline 
 143 ± 3 a   99 ± 3 b   <0.01  142 ± 4  117 ± 4  105 ± 4   <0.01 
Data are means ± SEM. Values sharing different superscripts within a row differ, as analyzed by two-way ANOVA and the Student-Newman-Keuls multiple  
comparisons test.
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Table 4.7.  Concentrations of amino acids in serum on Days 100, 121 and 140 of pregnancy in control ewes with different litter sizes 
 Day of pregnancy   Litter size  
Amino acid 
 100 121 140 P value  Twins Triplets Quadruplets P value 
Aspartate 
     4.8 ± 0.6    4.3 ±0.6    4.5 ± 0.8 0.57      5.1 ± 1    4.8 ± 0.7     3.8 ± 1 0.62 
Glutamate 
   84 ± 4 b 108 ± 4 a   47 ± 6 c   <0.01    89 ± 6   81 ± 4   68 ± 6 0.07 
Asparagine 
   39 ± 3 a   29 ± 3 b   29 ± 4 ab 0.04    34 ± 5   34 ± 3   28 ± 5 0.57 
Serine 
   65 ± 5   66 ± 4   54 ± 6 0.14    61 ± 7   67 ± 5   58± 7 0.58 
Glutamine 
 189 ± 10 a 136 ±10 b 221 ± 15 a   <0.01  194 ± 13 189 ± 9 163 ± 15 0.26 
Histidine 
   36 ± 3   37 ± 3   39 ± 3 0.61    36 ± 5   35 ± 3   41 ± 4 0.62 
Glycine 
 369 ± 23 342 ± 23 343 ± 37 0.50  391 ± 42 292 ± 26 372 ± 38 0.10 
Threonine 
   76 ± 9 a   71 ± 8 a   42 ± 11 b 0.03    77 ± 15   47 ± 10   65 ± 14 0.27 
Citrulline 
 114 ± 12 114 ± 11   88 ± 15 0.20  128 ± 20   98 ± 13   90 ± 19 0.37 
Arginine 
 144 ± 8 149 ± 8 157 ± 9 0.17  154 ± 15 139 ± 10 157 ± 13 0.49 
-Alanine 
   10 ± 1 b   12 ± 1 a   14 ± 1 a <0.01    11 ± 2   12 ± 1   13 ± 2 0.76 
Taurine 
 133 ± 9 a   99 ± 9 b   95 ± 12 b <0.01  110 ± 15   97 ± 10 120 ± 14 0.42 
Alanine 
 159 ± 17 157 ± 17 153 ± 22 0.94  147 ± 31 ab 211 ± 21 a 111 ± 29 b 0.04 
Tyrosine 
   67 ± 9   70 ± 9   60 ± 13 0.75    52 ± 16 b   96 ± 11 a   50 ± 15 b 0.04 
Tryptophan 
   28 ± 3   28 ± 3   24 ± 4 0.47    29 ± 5   29 ± 3   22 ± 4 0.48 
Methionine 
   14 ± 2   15 ± 1   14 ± 2 0.73    13 ± 3   16 ± 2   15 ± 2 0.67 
Valine 
   94 ± 10   98 ± 10   93 ± 12 0.88    83 ± 18 107 ± 12   93 ± 16 0.51 
Phenylalanine 
   34 ± 3   37 ± 3   36 ± 3 0.37    33 ± 5   38 ± 3   36 ± 5 0.73 
Isoleucine 
   57 ± 7   68 ± 6   76 ± 9 0.24    51 ± 8 b   87 ± 5 a   63 ± 8 b 0.03 
Leucine 
   77 ± 8 b   92 ± 8 a 103 ± 10 a 0.04    77 ± 14   99 ± 9   96 ± 13 0.44 
Ornithine 
   50 ± 5 a   43 ± 5 a   28 ± 7 b 0.02    48 ± 9   34 ± 6   39 ± 8 0.46 
Lysine 
 100 ± 9 a   89 ± 9 ab   71 ± 12 b 0.04    84 ± 17   83 ± 11   93 ± 15 0.87 
Cysteine 
   93 ± 2 a   87 ± 2 b   82 ± 3 b <0.01  101 ± 4 a   86 ± 3 b   75 ± 4 c <0.01 
Proline 
 109 ± 2 a 99 ± 2 b 88 ± 2 c <0.01  124 ± 4 a 94 ± 3 b 78 ± 4 c <0.01 
Data are means ± SEM. Values sharing different superscripts within a row differ, as analyzed by two-way ANOVA for repeated measures and the Student-Newman-Keuls 
multiple comparisons test. 
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Day 121 of pregnancy.  Serum levels of glycine and citrulline decreased (P < 
0.05) in triplet and quadruplet pregnancies, whereas threonine was lower in 
triplets, but did not differ (P > 0.05) between twin and quadruplet pregnancies 
(Table 4.6). 
When data from control ewes were analyzed (Table 4.7), concentrations 
of cysteine and proline in serum decreased (P ≤ 0.001) with increasing litter size, 
whereas levels of tyrosine and isoleucine were greater (P < 0.05) in the serum of 
ewes carrying triplets than in ewes carrying twins or quadruplets.  In addition, 
concentrations of alanine were lower (P < 0.05) in ewes carrying quadruplets, 
when compared with triplet pregnancies.  Litter size had no effect on 
concentrations of other amino acids in saline-infused ewes (Table 4.7).  
Concentrations of several amino acids in serum from control ewes 
changed throughout gestation.  Circulating levels of glutamate increased 
between Days 100 and 121 of pregnancy, but then fell abruptly at Day 140 (P < 
0.01; Table 4.7).  Conversely, concentrations of asparagine decreased (P < 
0.05) between Days 100 and 121, while no differences were found between 
Days 121 and 140 (Table 4.7).  Glutamine also decreased (P < 0.05) between 
Days 100 and 121 of gestation, but increased (P < 0.05) at Day 140 to values 
similar to those found at Day 100.  Serum levels of leucine and -alanine were 
greater (P < 0.01), but those of taurine and cysteine were lower (P < 0.01), on 
Days 121 and 140 of gestation, when compared with Day 100 (Table 4.7).  In 
contrast, concentrations of threonine and ornithine were lower (P < 0.05) at Day 
140, when compared with Day 100 or Day 121 of pregnancy.  Serum levels of 
lysine and proline decreased (P < 0.05) with the advancement of pregnancy 
(Table 4.7). 
 
Concentrations of other metabolites and hormones in maternal serum 
Table 4.8 summarizes concentrations of insulin and GH, as well as 
metabolites other than amino acids in maternal serum of both control and 
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arginine-infused ewes at Day 121 of pregnancy.  Intravenous infusion of arginine 
to prolific ewes reduced (P ≤ 0.05) the concentrations of BHB and ammonia, but 
had no effect on FFA, glycerol, triglycerides, glucose, lactate, urea, insulin or 
GH.  Concentrations of BHB were greater (P < 0.05) in mothers carrying 
quadruplets than in those with triplets (P < 0.05), whereas concentrations of FFA 
and ammonia increased (P < 0.05) with increasing litter size.  Similarly, 
concentrations of lactate increased (P < 0.01) by 207% as the number of fetuses 
increased from two to four per ewe.  Litter size had no effect on concentrations 
of glucose, glycerol, triglycerides, urea, insulin, or GH in prolific ewes.  
 Data from control ewes between Days 100 and 140 of gestation are 
summarized in Table 4.9. Concentrations of BHB (P = 0.57), FFA (P < 0.01) and 
glycerol (P < 0.01) were greater (P < 0.01) at Day 140 than Day 100 of 
pregnancy; whereas lactate was lower (P < 0.01) at Day 121.  There was no 
effect of day of pregnancy on concentrations of glucose in serum of saline-
infused ewes (Table 4.9).  Interestingly, concentrations of insulin increased (P < 
0.05) gradually, while those of GH decreased (P < 0.01) progressively between 
Days 100 and 140 of gestation.  Levels of triglycerides, urea or ammonia did not 
differ (P > 0.1) during this 40-day period of late pregnancy.  Between Days 100 
and 140 of gestation, litter size did not affect (P > 0.05) concentrations of 
glycerol, lactate, triglycerides, urea, insulin or GH in serum of control ewes.  
However, concentrations of BHB (P = 0.057) and FFA (P < 0.01) increased, but 
concentrations of glucose decreased, in ewes carrying quadruplets when 
compared with ewes with twins or triplets.  In addition, serum levels of ammonia 
increased progressively (P < 0.01) with increasing litter size (Table 4.9). 
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Table 4.8.  Concentrations of metabolites and hormones in serum in arginine-treated (345 mol/Kg body weight) and  
control ewes at one hour after injection on Day 121 of pregnancy 
Metabolites        
and  Treatment goup   Litter size  
Hormones  Arginine Control P values  Twins Triplets Quadruplets P value 
BHB (mM) 
     0.6 ± 0.1 b    1 ± 0.2 a 0.05      0.7 ± 0.2 ab    0.5 ± 0.1 b    1 ± 0.2 a  0.03 
FFA (µM) 
 369 ± 47 433 ± 61 0.42  224 ± 71 c 430 ± 61 b 549 ± 68 a  0.01 
Glucose (mM) 
    2.6 ± 0.1    2.3 ± 0.2 0.17      2.6 ± 0.2    2.6 ± 0.2    2.2 ± 0.2  0.28 
Glycerol (M) 
   34 ± 3   37 ± 4 0.63    26 ± 5   37 ± 4   43 ± 5  0.07 
Lactate (mM) 
    1.5 ± 0.2    1 ± 0.2 0.20      0.7 ± 0.3 b    0.9 ± 0.2 b    2.2 ± 0.2 a   <0.01 
Triglycerides (M) 
 330 ± 32 292 ± 39 0.45  370 ± 48 262 ± 41 302 ± 42  0.24 
Urea (mM) 
    6.6 ± 0.3    6.5 ± 0.4 0.93     6.7 ± 0.5    7.0 ± 0.4    5.9 ± 0.4  0.14 
Ammonia (µM) 
   97 ± 2.6 b 108 ± 3.2 a 0.01    83 ± 3.9 c 100 ± 3.3 b 126 ± 3.5 a <0.01 
Insulin (ng/L) 
 675 ± 108 565 ± 134 0.53  788 ± 164 636 ± 139 436 ± 145  0.28 
GH (ng/ml) 
    3.0 ± 0.2    3.1 ± 0.2 0.60      3.1 ± 0.3    3.0 ± 0.3    3.0 ± 0.3  0.97 
Data are means ± SEM. Values sharing different superscripts within a row differ, as analyzed by two-way ANOVA and the  
Student-Newman-Keuls multiple comparisons test. 
BHB= -Hydroxybutyrate, FFA= Free Fatty Acids, GH= Growth Hormone 
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Table 4.9.  Concentrations of metabolites and hormones in serum on Days 100, 121 and 140 of pregnancy in control ewes with different 
litter sizes 
Metabolites         
and  Day of pregnancy   Litter size  
Hormones  100 121 140 P value  Twins Triplets Quadruplets P value 
BHB (mM) 
     0.5 ± 0.2 b     0.9 ± 0.2 ab    1.2 ± 0.2 a 0.05     0.5 ±0.1 b     0.5± 0.03b    1.5 ± 0.05a 0.05 
FFA (µM) 
 350 ± 50 b 434 ± 53 b 774 ± 74 a  <0.01  342 ± 76 b 468 ± 52 b 749 ± 81a <0.01 
Glucose (mM) 
     2.3 ± 0.1     2.3 ± 0.1    1.8 ± 0.2 0.07     2.4 ± 0.2 a     2.4 ± 0.1 a    1.6 ± 0.2 b 0.01 
Glycerol (M) 
   36 ± 7 b   37 ± 7 b   88 ± 11 a  <0.01    43 ± 10   46 ± 7   70 ± 11 0.14 
Lactate (mM) 
     2.1 ± 0.2 a     1.1 ± 0.2 b    1.4 ± 0.3 b <0.01     1.7 ± 0.3     1.3 ± 0.2    1.6 ± 0.4 0.74 
Triglycerides (M) 
 301 ± 28 292 ± 28 254 ± 43 0.63  342 ± 40 265 ± 27 240 ± 43 0.21 
Urea (mM) 
     7.0 ± 0.4     6.5 ± 1.4    6.4 ± 0.6 0.69     6.8 ± 0.4     6.7 ± 0.3    6.4 ± 0.5 0.78 
Ammonia (µM) 
 109 ± 2.3 108 ± 2.3 109 ± 3.4 0.96    84 ± 2.2 c 114 ± 1.6 b 129 ± 2.7 a <0.01 
Insulin (ng/L) 
 639 ± 114 a 707 ± 127 b 356 ± 141c 0.03  621 ± 218 563 ± 140 518 ± 205 0.94 
GH (ng/ml) 
     2.7 ± 0.2 c     3.1 ± 0.2 b    3.9 ± 0.3 a <0.01     3.0 ± 0.2     3.3 ± 0.2    3.4 ± 0.3 0.57 
Data are means ± SEM. Values sharing different superscripts within a row differ, as analyzed by two-way ANOVA for repeated measures and the 
Student-Newman-Keuls multiple comparisons test. 
BHB= -Hydroxybutyrate, FFA= Free Fatty Acids, GH= Growth Hormone 
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Discussion 
An increase in the number of gestating fetuses has an adverse effect on 
intrauterine growth and survival in mammals, including humans and sheep 
(Blickstein, 2005; Gootwine et al., 2007).  Surprisingly, there are currently no 
effective methods of prevention or treatment for IUGR in human medicine or 
animal agriculture.  To our knowledge, the present study is the first to determine: 
1) the impact of litter size on concentrations of amino acids and other 
metabolites in maternal serum; and 2) the effect of intravenous arginine infusion 
during late gestation (a period of rapid fetal growth) on pregnancy outcomes in 
prolific ewes.  Parenteral administration of arginine was adopted to avoid 
extensive catabolism of arginine in the small intestine (Wu et al., 2007a) and 
effectively increase circulating levels of arginine.  Such an intervention is also 
applicable to pregnant women with persistent severe nausea and vomiting.  
There are three major findings from the current study.  First, concentrations of -
hydroxybutyrate, FFA, ammonia, cysteine, and proline in maternal serum were 
altered markedly by the number of fetuses in the litter.  Second, intravenous 
infusion of arginine between Days 100 and 121 of gestation reduced fetal death 
and improved fetal survival in ewes carrying multiple fetuses.  Third, arginine 
intervention greatly enhanced fetal growth of quadruplets, without affecting 
maternal body weight.  These novel findings not only provide a new approach to 
enhance sheep production, but also have important implications for human 
medicine. 
 Concentrations of ammonia, fatty acids and BHB in maternal serum 
increased substantially with litter size in control ewes (Table 4.9), suggesting 
that ewes carrying multiple fetuses adapted to increasing fetal demands for 
nutrients by mobilizing maternal protein and fat stores.  Interestingly, 
homeostasis of most amino acids (Table 4.7) in maternal serum was maintained, 
independent of the number of fetuses, indicating that rates of dietary provision 
and endogenous synthesis were closely matched by rates of utilization.  These 
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results are important because they suggest that any alterations in uterine and 
placental uptakes of amino acids in prolific ewes are not likely attributable to 
changes in their concentrations in maternal serum, but rather result from 
changes in utero-placental blood flow and nutrient delivery.  Similarly, there is 
evidence that reduced activities of placental transport, rather than changes in 
circulating concentrations, are primarily responsible for reduced transfer of 
amino acids from mother to fetus (Bajoria et al., 2001).  Notably, in the control 
ewes, cysteine and proline were the only amino acids that exhibited a 
progressive decrease in maternal plasma independent of litter size (Table 4.7).  
As a substrate for the synthesis of pyrroline-5-carboxylate (a regulator of cellular 
redox state) and polyamines, proline is now known to play an important role in 
conceptus growth and development (Wu et al., 2008).  Additionally, because 
cysteine is the most limiting amino acid for the synthesis of glutathione (an 
antioxidant) (Wu et al., 2004a), our findings raised the question of whether 
increased oxidative stress in ewes with multiple fetuses is a significant factor 
contributing to impaired uteroplacental blood flow and fetal growth.  The ewe will 
provide a useful model to examine placental vasculature and quantify utero-
placetal blood flow in dams carrying multiple fetuses. 
Arginine serves as a common precursor for the synthesis of nitric oxide 
(NO, a vasodilator and a signaling molecule) and polyamines (key regulators of 
DNA and protein synthesis) that are crucial for placental angiogenesis and 
growth in mammals (Wu & Morris, 1998; Sheppard et al., 2001; Ishikawa et al., 
2007; Wu et al., 2007a).  Thus, alterations in the arginine-NO and polyamine 
pathways could contribute to impaired uteroplacental blood flow and IUGR both 
in animal models and in humans (Sooranna et al., 1995; Kwon et al., 2003b; Wu 
et al., 2006).  Using sheep as a model, we observed that intravenous infusion of 
arginine enhanced fetal growth in ewes carrying quadruplets, which 
corresponded with the most severe IUGR under the present experimental 
conditions (Table 4.5).  The arginine treatment also increased the percentage of 
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live-born lambs by approximately 60% (Table 4.4), perhaps by improving the 
intrauterine environment (including metabolic status and oxygen supply) for fetal 
development.  Interestingly, intravenous infusion of arginine into underfed ewes 
with singletons also stimulated fetal growth (Chapter III).  These results further 
support the notion that metabolic regulation can be an effective means to 
prevent IUGR (Wu et al., 2004a).  In multiple fetuses, a 23% increase in birth 
weight would translate into a significant benefit in terms of growth and survival of 
neonates (Blickstein, 2005).  In contrast to ewes with quadruplets, arginine 
treatment did not affect fetal growth in ewes carrying twins or triplets (Table 4.5).  
Thus, it is likely that the effect of arginine on fetal growth and development 
depends on factors (e.g., the relative severity of uterine crowding, IUGR, and 
ketosis) other than circulating levels of arginine. 
At present, it is unknown how arginine promoted fetal growth in ewes 
carrying quadruplets.  However, the improved pregnancy outcome was 
associated with an increase in concentrations of arginine, cysteine, ornithine, 
and proline in maternal serum on Day 121 of pregnancy (Table 4.6), as well as a 
decrease in circulating levels of ammonia and BHB (Table 4.8).  As noted 
above, cysteine may enhance anti-oxidant capacity through the synthesis of 
glutathione.  Additionally, ornithine would facilitate the detoxification of ammonia 
(a highly toxic substance at elevated levels) via the urea cycle (Wu & Morris, 
1998).  Also, proline regulates intracellular redox state and placental function 
(Wu et al., 2008).  Further, hepatic ketogenesis, which contributes to metabolic 
acidosis, is under the control of insulin (Foster & McGarry, 1983).  Although 
serum levels of insulin did not differ between saline- and arginine-infused ewes 
in this study (Table 4.8), a nearly three-fold increase in maternal concentrations 
of arginine in arginine-treated ewes can markedly augment systemic NO 
synthesis (Wu & Meininger, 2002).  Because physiological levels of NO increase 
tissue sensitivity to insulin (Jobgen et al., 2006), parenteral administration of 
arginine may be capable of reducing hepatic ketogenesis, which was reflected 
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by a 41% decrease in concentrations of BHB in maternal serum (Table 4.8).  
This may be an important factor contributing to the enhanced survival of fetal 
lambs born to ewes carrying multiple fetuses (Table 4.4).  
On the basis of our current knowledge about the regulation of NO 
synthesis in endothelial cells (Wu & Meininger, 2002), increasing concentrations 
of arginine in maternal plasma of prolific ewes are expected to increase utero-
placental blood flow (Neri et al., 1995).  This, in turn, would enhance the transfer 
of oxygen and nutrients from maternal to fetal circulations.  Elevation of utero-
placental blood flow through intramuscular administration of Sildenafil citrate to 
underfed ewes between Days 28 and 112 of gestation has been reported to 
enhance concentrations of nutrients in fetal plasma and fluids, as well as fetal 
growth (Satterfield et al., 2007).  Sildenafil citrate, which acts to enhance 
intracellular cGMP availability by inhibiting phosphodiesterase-5 (an enzyme that 
hydrolyzes cGMP to GMP), increased utero-placental blood flow via the protein 
kinase G signaling pathway (Wareing et al., 2005).  Because catheterization of 
fetal vessels for blood sampling could affect fetal growth, we chose not to 
perform this invasive procedure in the present study.  Therefore, precise 
changes in concentrations of nutrients in fetal circulation, as well as amniotic 
and allantoic fluids, due to intravenous infusion of arginine into prolific ewes 
were not determined.  Additional studies are warranted to test the hypothesis 
that parenteral administration of arginine increases uteroplacental blood flow 
and, thus, the supply of nutrients transferred across the placenta from mother to 
fetus. 
In conclusion, parenteral administration of arginine between Days 100 
and 121 of pregnancy improved the survival rate of lambs born to ewes 
gestating multiple fetuses and increased the birth weights of quadruplets. These 
results have important implications for both human medicine and sheep 
production.  Particularly, the findings provide a basis for the use of arginine as a 
therapeutic intervention to improve pregnancy outcomes, under conditions of a 
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severely stressed uterine environment, in women and ewes gestating multiple 
fetuses.  
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CHAPTER V 
SUMMARY AND DIRECTION OF FUTURE RESEARCH 
 
Intrauterine growth restriction (IUGR) accounts for a large incidence of 
infant mortality and morbidity worldwide and may be associated with an 
increased risk of metabolic and physiological disorders later in life (Barker & 
Clark, 1997; Ozanne & Hales, 2002; Bryan & Hindmarsh, 2006; Eleftheriades et 
al., 2006).  An effective therapeutic strategy to ameliorate or prevent this 
condition is still lacking, which results in a vast emotional, clinical and economic 
toll (Ergaz et al., 2005; Gluckman & Hanson, 2006; Mari & Hanif, 2007).  
Furthermore, IUGR is also a major concern in animal agriculture where it 
severely impacts animal survival and health, as well as general production and 
performance efficiencies (Wu et al., 2006). 
This dissertation research tested the hypothesis that parenteral 
administration of arginine during mid- to late gestation is effective in enhancing 
fetal growth and hence weight at birth of IUGR lambs. Undernourished or prolific 
ewes were used as experimentally-induced and naturally-occurring ovine 
models of IUGR, respectively.  Parenteral administration of arginine was 
adopted in this work to avoid extensive catabolism of arginine in the rumen and 
small intestine (Wu et al., 2007a), hence effectively increasing circulating levels 
of arginine.  However, it is important to indicate that intravenous administration 
of any substance, particularly if long-term catheterization of peripheral vessels is 
used, can cause unfavorable complications (e.g., phlebitis and thrombosis), 
which predispose to catheter-associated bacteremias.  Catheter complications 
often arise during the experimental period in livestock, increasing the number of 
animals necessary to complete a study (Barraza et al., 2006), and must always 
be considered when contemplating protocols involving central venous access. In 
addition, although arginine is generally well-tolerated when administered via the 
intravenous route, local irritation and phlebitis may occur due to the high 
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osmolality of the solution, and accidental extravasation may lead to local tissue 
injury (Baker & Franklin, 1991; Boger & Bode-Boger, 2001).  This problem is 
ameliorated when low concentrations of arginine are infused intravenously into 
animals over a prolonged period of time. Thus, mode and interval of 
administration of arginine must be considered in the experimental design. 
Because arginine has an alkaline property, its hydrochloride salt is 
generally used for intravenous administration (Wu & Meininger, 2000).  However 
solutions of arginine hydrochloride used for infusion have a high chloride content 
that could affect the metabolism and health of mother and fetus and may be 
hazardous in individuals with an electrolyte imbalance (Boger & Bode-Boger, 
2001).  In addition, the biological half-life of arginine is relatively short due to its 
degradation by arginase in virtually all cells (Wu & Morris, 1998; Wu et al., 
2007a).  Hence, the initial experiment was designed to establish if parenteral 
administration of citrulline to late pregnant ewes is an effective alternative 
approach to enhance circulating concentrations of available arginine in maternal 
and fetal plasma.  Additionally, the pharmacokinetics of citrulline and arginine in 
maternal plasma in response to administration of an intravenous bolus of either 
amino acid to ewes were determined (Chapter II).  A prolonged increase in 
concentrations of arginine and citrulline was maintained in maternal and fetal 
plasma after citrulline administration to ewes, whereas the increase in 
concentrations of arginine in fetal and maternal plasma declined more rapidly 
after arginine infusion.  This was consistent with pharmacokinetic results 
indicating that the half-life of citrulline was twice that of arginine in ewes.  These 
findings revealed that intravenous administration of citrulline to pregnant ewes is 
more effective than that of arginine in maintaining high concentrations of 
available arginine in maternal and fetal circulations, and provide a basis for the 
design of alternative therapeutic strategies to ameliorate IUGR in mammals. 
The second experiment was conducted to determine if intravenous 
administration of arginine to underfed ewes prevented fetal growth restriction 
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(Chapter III).  Global nutrient restriction of 50% of the National Research Council 
(1985) maintenance requirements for pregnant sheep leads to IUGR (Vonnahme 
et al., 2003; Kwon et al., 2004a; Satterfield et al., 2007).  Results from this study 
indicated that parenteral administration of arginine to underfed ewes enhanced 
birth weights of lambs by 21% compared with saline-infused underfed ewes.  
Moreover, there was no difference in birth weights of lambs between the control-
fed and the arginine-infused underfed ewes. In addition, intravenous 
administration of arginine to underfed ewes increased concentrations of arginine 
(69%), ornithine (55%), proline (29%), methionine (37%), leucine (36%), 
isoleucine (35%), cysteine (19%), and free fatty acids (43%) in maternal serum, 
and decreased levels of ammonia (18%) and triglycerides (32%).  Under these 
experimental conditions, administration of arginine to underfed ewes prevented 
fetal growth restriction without affecting maternal body weight, indicating that 
arginine treatment enhanced the availability of nutrients to support fetal growth, 
as well as overall efficiency of nutrient utilization by the dam.   
The third experiment was designed to assess the effects of administration 
of arginine to late pregnant mothers on fetal survival and birth weights of lambs 
born to ewes with multiple fetuses.  The frequency of multiple fetuses has 
increased in human pregnancies due to assisted reproductive technologies, 
consequently increasing the incidence of premature and low birth-weight infants 
(Blickstein, 2005; Siddiqui & McEwan, 2007).  Furthermore, improvements in 
sheep breeding have resulted in new breeds with increased litter size, but 
reduced fetal survival and birth weight (Gootwine et al., 2007).  Intravenous 
administration of arginine three times daily from Day 100 to Day 121 of 
pregnancy to ewes carrying multiple fetuses improved survival rate of lambs by 
59%.  In addition, arginine treatment enhanced fetal growth of quadruplets, 
which was reflected by a 23% increase in birth weights, without affecting 
maternal body weight.  The improved pregnancy outcome was associated with 
an increase in concentrations of arginine, ornithine, cysteine and proline, as well 
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as a decrease in circulating levels of ammonia and -hydroxybutyrate in 
maternal plasma.  These results indicate that parenteral administration of 
arginine to prolific ewes improved pregnancy outcome and ameliorated fetal 
growth restriction under conditions of a severely stressed uterine environment, 
perhaps by modulating metabolic pathways and improving intrauterine nutrient 
availability for fetal development. 
Collectively, results of research for this dissertation indicate that arginine 
treatment improves pregnancy outcome and enhances birth weights of lambs 
born to undernourished and prolific ewes that served as ovine models of IUGR. 
In addition, the results provide support for the study of the clinical use of arginine 
as a therapeutic strategy to prevent or ameliorate IUGR in mammals and 
highlight the need for additional studies to investigate cellular and molecular 
mechanisms that could be responsible for the beneficial effects of arginine in 
regulating fetal growth and development.  Additionally, future research should 
focus on a role for arginine in placental development, as well as uteroplacental 
blood flow and the supply of nutrients from mother to fetus.  Furthermore, 
detailed studies to investigate single or multiple interventions at specific stages 
of gestation or even the periconceptual period could clarify potential 
mechanisms whereby arginine influences growth and development of the 
conceptus, as well as the relative contributions of altered substrate supply on 
fetal growth and on the physiological adaptations that impact neonatal survival 
and predispose to adult onset disease.  Moreover, the use of functional 
genomics to focus on arginine metabolism at specific stages of pregnancy in 
small and eventually large animal models should facilitate understanding the 
mechanisms for fetal adaptation to perturbations of the intrauterine environment, 
and identify similarities and differences among species.  Finally, alternative 
approaches such as the use of citrulline supplementation in IUGR animal 
models should be evaluated to develop therapeutic strategies. 
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